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ABSTRACT 
Estephan Jose Moana-Filho: Brain Micro- and Macro-Structural Characteristics 
Investigation in Fibromyalgia Using Multi-Modal Magnetic Resonance Imaging 
(Under the direction of Richard H. Gracely) 
Fibromyalgia (FM) is a chronic widespread pain condition that deeply impacts the 
lives of patients. Multiple symptoms such as fatigue, impaired cognition, and sleep 
disturbances among others are commonly described. Despite intensive research effort, 
no disease-specific mechanism uniquely explains the clinical presentation of FM. 
Nonetheless, current evidence points to a major role of the central nervous system for 
the main feature of this condition: pain and sensory augmentation. Neuroimaging 
techniques provide a window into the brain mechanisms that may play a role in FM. 
Several studies using functional magnetic resonance imaging (MRI) show abnormalities 
in pain processing in the brain of FM patients. Likewise, structural abnormalities are 
found using anatomical MRI however the findings are less consistent. The main goal of 
this dissertation was to comprehensively assess brain structural features of FM patients 
and matched controls at both micro- (cellular-level structures such as membranes, 
myelin as well as axonal density) and macro-structural (gross anatomical) levels as 
measured by diffusion-weighted and high-resolution anatomical MRI respectively. 
The results from diffusion MRI show evidence of widespread micro-structural 
white matter (WM) abnormalities in the brains of FM patients compared to controls, and 
also within relevant pain-related brain regions. These findings give support to the view 
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that alterations in the brain of patients potentially contribute to the symptoms 
experienced by them. Conversely, macro-structural brain features showed little 
difference between patients and controls regarding gray matter (GM) characteristics. 
Between-group differences were only found for increased volume in the amygdalae and 
WM adjacent to the anterior cingulate cortex and left insula for FM patients relative to 
controls. 
Taken together these findings may indicate that structural abnormalities in the 
brain of FM patients are more widespread in the micro-structural level, while regional 
differences limited to subcortical structures and WM adjacent to pain-related cortical 
areas are more typical at the macro-structural level with no measurable impact to GM 
morphological characteristics. 
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CHAPTER 1: INTRODUCTION, METHODS OVERVIEW AND SUBJECT 
SAMPLE DESCRIPTION 
Introduction 
When one ponders on the meaning of the word “pain”, some possibilities arise. It 
could refer to the conscious experience related to bodily injury or disease processes, 
which is probably one of the most common interpretations. Another possible meaning 
would be the discomfort associated with unpleasant feelings, such as the separation 
from a spouse or the mourning of a loved one. This dichotomous view on pain is 
present for millennia, dating from the times of the ancient Greek philosophers such as 
Aristotle (Perl, 2007; Cervero, 2009). In the last centuries, competing pain theories 
developed describing distinct features: i. Following a noxious stimulus in peripheral 
tissues (e.g., skin), dedicated pain receptors in the periphery detect and transmit the 
noxious input through pain specific pathways to the brain (specificity theory); ii. 
Peripheral stimulus intensity as transduced by unspecialized afferent fibers would 
dictate a non-painful (innocuous stimulus) or painful (intense stimulus) perception 
according to the level of neuronal discharge (intensity theory); or iii. Peripheral receptors, 
irrespective of sensory input modality, following an intense stimulation would trigger a 
sequence of impulses in peripheral and central neurons in particular spatial and 
temporal patterns such as to convey a pain percept (pattern theory) (Perl, 2007). In the 
last 50 years, several lines of evidence showed that neither theory alone could explain 
all pain-related mechanisms and that likely both specificity and pattern concepts must 
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be considered to some extent in different scenarios of clinical and experimental pain 
(Prescott et al., 2014). 
The complexity of the pain phenomenon is well recognized currently, where the 
view of it as a dedicated “alarm system” that serves solely a protective function for 
survival and well being is not sufficient. Pain is now considered a multi-dimensional 
experience, that includes sensory-discriminative, affective-motivational and cognitive-
evaluative components (Treede et al., 1999). This multidimensionality is embedded 
within the definition of pain provided by the International Association of Pain (IASP) 
(Merskey and Bogduk, 1994): 
“An unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage.” 
This definition includes distinct aspects related to pain: it is a subjective (i.e., 
personal and individualized) experience that encompasses both sensory and emotional 
components, and tissue damage does not necessarily have to take place. Given this 
inherent intricacy, it is not a surprise that several types of pain exist such as nociceptive, 
inflammatory or neuropathic (Cervero and Laird, 1991; Cervero, 2009). The first two 
types of pain are considered physiological and serve to protect an individual from harm. 
Neuropathic pain however, where even innocuous peripheral stimuli can evoke pain, 
can be considered a neurological disease secondary to damage or dysfunction of the 
peripheral and/or central nervous systems. 
Another important distinction related to the pain experience is between acute and 
chronic. The former usually has a known causal factor and is expected to reduce over 
time as the healing process ensues; the later is present beyond the expected tissue 
healing time (e.g., over 3 months), appears to have no useful purpose to an individual 
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and can be seen as a pathological process (Davis, 2013), with ample evidence of 
associated functional, structural and neurochemical brain changes (Tracey and 
Bushnell, 2009). The processes related to the transition from acute to chronic pain are 
not completely understood (Mifflin and Kerr, 2014), nonetheless predictors of this 
transition are under investigation (Apkarian et al., 2013). 
The aforementioned complexity of pain is well represented in puzzling clinical 
conditions considered together under the term “functional somatic syndrome”. It refers 
to related syndromes where symptoms, suffering and disability better characterize the 
clinical presentation than disease-specific structural or functional abnormalities (Barsky 
and Borus, 1999). Functional somatic syndromes (FSS) usually are not present in 
isolation but rather with one or more comorbid pain conditions (Wessely et al., 1999; 
Aaron and Buchwald, 2001), and previous diagnosis of a FSS is a strong risk factor for 
other FSSs (Warren et al., 2013). These associations of comorbid pain conditions likely 
represent underlying common pathophysiological mechanisms (Yunus, 2007), and 
studies based on mechanism-driven hypotheses might help understand each 
condition’s peculiarity beyond those shared general mechanisms (Croft et al., 2007). 
Most reports describing FSSs, if not all, include fibromyalgia. Fibromyalgia (FM) 
can be considered a prototypical FSS (Ablin et al., 2012), that is mainly characterized 
by chronic widespread body pain and associated symptoms that includes fatigue, sleep 
disturbances and cognitive dysfunction with no measurable organic cause sufficient to 
explain those symptoms (Clauw, 2009). Concerted research efforts to elucidate the 
pathophysiology of FM took place in the past decades, and several concepts proposed 
for this condition have been reformulated or abandoned based on the recent evidence 
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gathered. What follows is a brief description of the history and current accepted 
knowledge of FM. 
Fibromyalgia: an overview 
Early studies of fibromyalgia 
Initial reports of a condition with similar clinical presentation as FM can be traced 
back to the beginning of the 20th century. Sir William Gowers provided a comprehensive 
description of what was known then about this condition and proposed naming it 
“fibrositis”, as it was believed to be some form of “inflammation of the fibrous tissue of 
the muscles” (Gowers, 1904). Almost fifty years later, Graham described the 
controversy surrounding “fibrositis” within the rheumatology specialty and how it 
became a “depot for many varieties of non-articular rheumatism” (Graham, 1953). Of 
note, he mentions the lack of evidence for an inflammatory etiology for this condition 
and therefore questioning the propriety of that term (“-itis” = inflammation). 
Moldofsky and colleagues provided interesting insights in systematically 
investigating sleep disturbances using electroencephalography (EEG) in FM patients 
and in healthy controls following sleep deprivation (Moldofsky et al., 1975). They 
reported a disruption in the EEG sleep pattern in FM patients named “alpha-delta” sleep, 
and that a 3-night sleep deprivation during the non rapid eye movement (REM) stages 
elicited musculoskeletal and mood symptoms in healthy controls similar to those seen in 
FM patients. Following recovering nights with undisrupted sleep, healthy controls 
experienced remission of those symptoms (Moldofsky et al., 1975). In a later study it 
was shown that while disruption during non-REM sleep could evoke FM-like symptoms 
in healthy controls, REM sleep disruptions could not (Moldofsky and Scarisbrick, 1976). 
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Following these observations, Smythe and Moldofsky proposed criteria for the 
diagnosis of “fibrositis”, that could differentiate FM patients from patients suffering from 
other diffuse pain syndromes, malingering or neuroticism (Smythe and Moldofsky, 1977). 
Many consider this seminal work the birth of the modern concept of FM (Clauw, 2009; 
Wolfe and Hauser, 2011). A comprehensive clinical description of 50 FM patients and 
50 age-, sex- and race-matched healthy controls was offered by Yunus and 
collaborators, where they also proposed using “fibromyalgia” as opposed to “fibrositis” 
given the lack of evidence for inflammation as a etiological factor for the so-called 
primary FM (i.e., “when no known cause or associated contributory disorder is present”) 
(Yunus et al., 1981). Additional early studies have shown no specific personality profile 
for FM patients, and that pharmacological (antidepressants, non-steroidal anti-
inflammatory drugs, chlorpromazine) and non-pharmacological (strenuous physical 
exercise) treatment modalities provided significant improvements in FM symptoms 
(McCain and Scudds, 1988). 
Fibromyalgia classification and diagnostic criteria 
A major advancement for FM research took place in 1990, when the American 
College of Rheumatology (ACR) criteria for the classification of fibromyalgia was 
published (Wolfe et al., 1990). It required a history of at least 3 months of widespread 
body pain and pain on digital palpation in 11 or more out of 18 tender point sites for an 
individual to be classified as having FM. These criteria allowed standardization of 
inclusion requirements for FM subjects in research studies, which provides more 
homogenous subject samples thus improving the comparability of findings across 
studies; however, they were not considered suitable for use in clinical practice as they 
 6 
might exclude patients that present several but not all signs and symptoms to meet the 
ACR 1990 FM classification criteria (Clauw, 2009). 
Partly to overcome this limitation and to address objections from different parties 
to the ACR 1990 FM classification criteria, new diagnostic criteria for FM were offered in 
2010 (Wolfe et al., 2010). The most significant change was removing the requirement 
for tender point examination and count. In addition, two metrics were developed: 1. 
Widespread pain index (WPI), where the investigator notes how many body areas (out 
of 19) the patient had pain in the last week; and 2. Symptom severity (SS) scale, that 
considers the severity of fatigue, waking unrefreshed and cognitive symptoms plus the 
extent of somatic symptoms in general (score range: 0-12). To satisfy the ACR 2010 FM 
diagnostic criteria a patient must meet three conditions: i. Either a WPI ≥ 7 and SS ≥ 5, 
or WPI 3-6 and SS ≥ 9; ii. Symptoms must be present at similar levels for at least 3 
months; and iii. No presence of other disorder that could explain the pain (Wolfe et al., 
2010). The authors stressed that these diagnostic criteria were not meant to replace the 
ACR 1990 criteria, but rather offer an alternative method of diagnosis. 
With the goal of developing criteria that allowed self-administration thus 
eliminating the need for an interviewer, a modification of the ACR 2010 diagnostic 
criteria was proposed (Wolfe et al., 2011). To achieve that goal, the SS scale was 
modified in a way that, instead of having a somatic symptoms list to check, patients 
respond “yes” or “no” to the presence of headaches, pain / cramps in the lower 
abdomen of depression symptoms in the last 6 months. Its score range was unchanged 
(0-12) though, as well the WPI was also virtually unchanged – except that now it is self-
administered. A new scale named FM symptom scale (FS) was proposed, which is 
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simply the sum of the WPI and the modified SS with a score range of 0-31; a score of ≥ 
13 was shown to have good sensitivity and specificity for identifying FM (Wolfe et al., 
2011). Given the self-administering feature of this modified criteria, the authors provided 
a cautionary note that this instrument does not serve as a self-diagnosis tool or 
substitutes a physician’s diagnosis. 
These recent criteria were received with mixed opinions, and several researchers 
argued about the added value they brought beyond that offered by the accepted ACR 
1990 FM classification criteria (Wolfe and Hauser, 2011; Abbi and Natelson, 2013; 
Hannonen, 2013). Nonetheless, these criteria are recognized as valuable instruments in 
designing studies that will help elucidate etiological factors, identify more homogenous 
subgroups of patients and develop targeted treatments (McBeth and Mulvey, 2012). 
A supplementary issue to the classification of FM is the recognition (or the lack 
thereof) of it as a valid clinical entity (Ablin et al., 2012). On one side are those who 
defend that FM is no more than a collection of symptoms, i.e., “aches and pain that all 
people often have” at some point in life (Ehrlich, 2003). On the opposite side are 
investigators who, although acknowledging the limitations in the available FM criteria 
and that those affected by this condition may be at “end of the bell-shaped curve”, 
understand that FM arises from altered pain processing mechanisms as shown by 
several studies (Harris and Clauw, 2006). In an article named “Fibromyalgia wars”, 
Wolfe explores the myriad of interests of different agents pro and against having FM as 
a legitimate diagnosis: patients, some specialty physicians vs. the majority of physicians, 
pharmaceutical companies, professional organizations, patients’ support groups, 
governmental agencies, and attorneys (Wolfe, 2009). When reading the available 
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literature on this topic, it becomes clear that FM is a controversial subject in the 
scientific and medical field, and that it impacts not only the affected patients but also the 
society at large. 
Etiology, pathophysiology and treatment of fibromyalgia 
Several studies have investigated the pathophysiology of FM, trying to determine 
etiological (i.e., causative) factors and pathophysiological (i.e., functional changes 
associated with a condition) mechanisms of this syndrome. Different investigational 
approaches brought some light on putative etiological factors in FM, even though some 
early studies tended to have relatively small samples that make interpretation of its 
results difficult. 
Genetic factors seem to play an important role in FM, given the familial 
aggregation found where having a relative with FM increased the odds of other relatives 
presenting it (Buskila and Neumann, 2005), with one study showing odds ratio of 8.5 
when compared to families with one member affected by rheumatoid arthritis (Ablin et 
al., 2006). Family members of FM patients are more sensitive to pain than controls, and 
they also have higher rates of comorbid conditions including irritable bowel syndrome 
(IBS), temporomandibular disorders (TMD), headaches or other regional pain 
syndromes (Clauw, 2009). Genetic polymorphisms were found in higher frequencies in 
FM patients for genes encoding the serotonin transporter (5-HTT), the serotonin 5-
HT2A receptor, cathecol-O-methyl transferase (COMT), the dopamine D4 receptor and 
the substance P receptor NK1 (Ablin et al., 2006). Recently a systematic review and 
meta-analysis of candidate genes in FM showed that polymorphism in the serotonin 2A 
receptor had significant association with FM susceptibility (overall odds ratio = 1.33), 
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while no associations were found for 5-HTT and COMT (Lee et al., 2012). Given the 
evidence for genetic factors in FM, some environmental triggers associated with FM 
have been described. Among those are physical trauma, some infections (mostly viral), 
and emotional stress (Clauw, 2009). 
Impairment of the stress responses and dysfunction of the hypothalamic-
pituitary-adrenal (HPA) axis are linked to FM, however the abnormalities found varies 
across studies (Clauw, 2009). Disturbances in the autonomic nervous system are 
described in FM including postural orthostatic tachycardia (Staud, 2008), hyperactivity 
at rest / hyporeactivity during stress (Martinez-Lavin, 2007), and abnormalities in heart 
rate variability (Staud, 2008; Lerma et al., 2011). Proinflammatory cytokines were found 
to be mildly increased in FM patients compared to controls, however the methodological 
quality of those studies was considered low thus preventing a better understanding on 
the role of cytokines in FM pathophysiology (Uceyler et al., 2011). 
Mood disorders like anxiety and depression are commonly reported in FM 
patients, but this could be attributed at least partly to sampling bias by selecting patients 
from tertiary care centers (Clauw, 2009). Sleep disturbances are part of the core 
symptoms of FM, and several recent studies provide additional support for the role of 
sleep based on questionnaires (Osorio et al., 2006; Munguia-Izquierdo and Legaz-
Arrese, 2011) and polysomnography (Shah et al., 2006) data. However, sleep 
measures determined by 24-hour actigraph use and sleep diary for 14 days failed to 
predict clinical pain levels (Anderson et al., 2012). 
Both peripheral and central sensitization have been implicated in the 
pathophysiology of FM pain, as reviewed by Staud and Rodriguez (Staud and 
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Rodriguez, 2006). An interesting finding was abnormalities related to the temporal 
summation of pain or “wind-up”, which is the increased pain sensation that arises when 
identically intense stimuli are presented repeatedly; it has been shown to result from 
central mechanisms that involve the N-methyl-D-aspartate (NMDA) receptor system. 
FM patients exhibit wind-up following experimental stimuli (mechanical, thermal, 
electrical) at lower frequencies and lower stimulus intensities than controls, and after 
sensations are more intense, longer-lasting and are more painful in patients (Staud, 
2006). 
In fact, augmented sensory and pain processing in FM is well supported by 
evidence. Using sophisticated psychophysical methodology in which stimuli 
presentation was done in a random fashion, Petzke and colleagues demonstrated that 
FM patients are more sensitive to pressure and heat than healthy controls (Petzke et al., 
2003) however the increased pain sensitivity is dissociated from pain unpleasantness 
ratings (Petzke et al., 2005). Sensitivity to other stimulus modalities such as cold and 
electrical are not different between FM patients and controls, however patients do 
exhibit lower thresholds to noxious auditory tones (Clauw, 2009). One potential 
explanation for the augmented pain processing in FM is a deficiency in endogenous 
analgesics system such as the diffuse noxious inhibitory controls (DNIC) (McBeth and 
Mulvey, 2012), and this might be related to impaired serotonergic and noradrenergic 
activity but not opioidergic activity - since the latter was found to be normal or even 
increased in FM (Clauw, 2009). 
Recently other factors have been investigated for their role in FM. Obesity is 
frequently observed in FM patients (Ursini et al., 2011), and it was found to reduce their 
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quality of life (Timmerman et al., 2013). Peripheral factors as part of FM etiology have 
been investigated before but the evidence provided was considered weak (Abeles et al., 
2007), however small nerve pathology got some attention in 2013 when two studies 
reporting this were published a few months apart. In the first study published by a 
German group (Uceyler et al., 2013), they used three methods (quantitative sensory 
testing, pain-related evoked potentials, and skin punch biopsies) that converged in 
supporting impaired small nerve fiber function in FM patients. The second study used 
standard tests for clinical diagnostic criteria of small-fiber polyneuropathy (distal-leg skin 
biopsy and autonomic function testing) in FM patients and matched controls (Oaklander 
et al., 2013), and showed that over 50% of FM patients exhibited evidence of small-fiber 
polyneuropathy compared to 17.2% of controls. The fact that two different groups found 
reproducible findings is promising, even though they are not in agreement of the specific 
pathology affecting small nerve fibers (Uceyler and Sommer, 2013). 
Neuroimaging studies have provided much new information about FM 
pathophysiology, and they will be addressed separately in a later section of this chapter. 
Treatment options for FM are numerous, since the above discussed mechanisms 
may play a role for the expression of FM symptoms in each patient in different degrees 
thus an individualized treatment plan is of utmost importance (Staud, 2007). Non-
pharmacological options include physical therapy modalities (thermal, electrical 
stimulation, massage, laser, acupuncture), cognitive behavioral therapy, complementary 
and alternative therapies (body-mind techniques, dietary supplementation, physical 
manipulation), and physical exercise (Casale et al., 2008). The latter has a good level of 
evidence in reducing FM symptoms like pain and fatigue and improving the quality of life 
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(Busch et al., 2011). The pharmacotherapy for FM reported in the literature is broad, 
including several categories such as analgesics, muscle relaxants, antidepressants, 
anticonvulsants, sedative-hypnotic drugs, among others; the evidence for benefit is 
equally diverse ranging from no efficiency to those showing strong evidence of benefit 
(Clauw, 2009). Three drugs are currently approved by the U.S Food and Drug 
Administration (FDA) for treatment of FM: pregabalin (an alpha2-delta calcium channel 
ligand), duloxetine and minalcipran (both are serotonin-norepinephrine reuptake 
inhibitors) (Hsu, 2011). Despite the numerous options for treatment, prognosis of FM is 
in general somber with limited improvements over periods of up to 10 years (McBeth 
and Mulvey, 2012). A study that followed 1,555 FM patients semi-annually with 
questionnaires for up to 11 years showed no clinically meaningful symptomatic 
improvement, however 25% had at least moderate improvement of pain over time 
(Walitt et al., 2011). It has been suggested that the prognosis might depend on where a 
particular FM patient falls within the disease severity spectrum (Clauw, 2009), and this 
must be taken into account when developing a treatment plan for each individual. 
Epidemiology and health care cost of fibromyalgia 
Several investigators have assessed epidemiology of FM in the past decades. 
Wolfe and collaborators reported a prevalence of 2% in the general population, with 
3.4% and 0.5% figures for women and men respectively (Wolfe et al., 1995). McBeth 
and Mulvey in their review report an estimate of patients with symptoms fitting FM 
criteria ranging between 2-22% for clinical populations, while prevalence estimates in 
the general population fall within 1-11% (McBeth and Mulvey, 2012). A recent review of 
the worldwide epidemiology of FM described several studies in different settings and 
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countries spanning four continents (Africa, the Americas, Asia and Europe) (Queiroz, 
2013). The estimated global mean prevalence of FM was 2.7% (range = 0.4 – 9.3%), 
with a mean prevalence for women of 4.2% and for men 1.4% (female:male ratio = 3:1). 
Incidence of FM was estimated in two studies only, with one reporting an incidence of 
5.83 new cases per 1,000 persons-years for females only while the other described 
numbers of new FM cases per 1,000 person-years as 11.28 for females and 6.88 for 
males (Queiroz, 2013). 
Health care costs associated with FM are higher when compared to non-FM 
patients. Using a U.S. health insurance database to determine characteristics and 
health care costs within a 12-month period, FM patients had three-fold higher mean cost 
and four times more doctor office visits when compared to non-FM patients (Berger et 
al., 2007). More recently, a retrospective study from the Quebec provincial health plans 
reported that the annual number of visits for FM patients was 25.1 with an associate 
cost of $ 4,065, while non-FM patients had a mean of 14.8 visits and costs of $ 2,766 
(Lachaine et al., 2010). 
Brain characteristics in fibromyalgia assessed by neuroimaging techniques 
Pain research in humans has benefited from recent advancements in 
neuroimaging, since it allows probing brain functional and structural characteristics in 
vivo with minimal to no invasiveness. Numerous neuroimaging technologies have been 
used for the study of pain including magnetic resonance imaging (MRI), positron-
emission tomography, magnetoencephalography, and EEG among others (Davis, 2011). 
These techniques are being used to unravel novel information on the brain plasticity 
secondary to chronic pain states (Lee and Tracey, 2013), and may also help parse out 
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complex genetic relationships through the concept of endophenotypes, i.e., a 
measurable component (such as neuroimaging measurements) of a clinical condition 
that has a more direct link to the underlying genetics than the condition itself (Tracey, 
2011). 
Diverse neuroimaging techniques have been used to investigate brain 
characteristics of FM patients, as the numerous reviews on the subject describe 
(Williams and Gracely, 2006; Cook et al., 2007; Nebel and Gracely, 2009; Gracely and 
Ambrose, 2011; Staud, 2011; Jorge and Amaro, 2012). Here the focus will be on MRI-
based modalities, as this dissertation uses only this technique. 
MRI generates images of the body through the use of strong magnetic fields and 
radiofrequency pulses. The well studied properties of hydrogen nuclei (which are 
abundant in the human body in water molecules) when placed within a strong magnetic 
field allows investigators to manipulate several variables in order to generate brain 
images with different characteristics. In a very crude description, MRI modalities can 
generate brain images through exploring distinct magnetic properties of brain tissues, 
e.g.,: i. In high-resolution structural imaging, the gray and white matter and cerebral 
spinal fluid (CSF) can be distinguished according to their unique magnetic relaxation 
time (T1); ii. Functional MRI (fMRI) can detect the levels of blood oxygenation across the 
brain to indirectly infer neuronal activity in real time with reasonable spatial resolution; 
and iii. Diffusion weighted imaging (DWI) can assess the micro-structure of brain tissues 
by measuring the diffusion of water molecules within it. Thus the broadest division of 
MRI modalities for the study of the brain is between functional and structural. Functional 
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MRI is sensitive to changes over time of neuronal activity, while structural MRI 
measures biophysical properties of local brain tissue (Smith et al., 2004). 
Stimulus-evoked fMRI studies in FM are abundant. The first such study was 
developed by Gracely and collaborators in 2002, using blunt pressure to the thumb nail 
as stimulus (Gracely et al., 2002). They used a pressure level able to evoke pain in 16 
FM patients, and used two pressure levels in 16 controls: higher pressure level in order 
to elicit comparable subjective pain ratings or a lower pressure level that matches that 
used for the FM patients. Brain activations were similar for both groups only when 
matched for subjective pain ratings (using much greater pressure for controls), while no 
common activations were found following matched pressure level stimuli in both groups. 
These results were replicated when painful heat was used as stimulus (Cook et al., 
2004). Other notable findings using fMRI following noxious thumb pressure stimulation 
in FM patients were association of depression (Giesecke et al., 2005) and 
catastrophizing (Gracely et al., 2004) scores to brain activations that failed to be 
reproduced in subsequent studies (Jensen et al., 2010; Burgmer et al., 2011), and also 
reduced activation in rostral anterior cingulate cortex compared to controls (Jensen et 
al., 2009). Other types of stimuli and cognitive tasks have been also used in fMRI 
studies with FM patients, along with resting-state BOLD studies where the functional 
connectivity of the brain is investigated and magnetic resonance spectroscopy to 
measure neurochemical metabolites to infer brain properties related to pathology and 
pharmacological manipulation (Gracely and Ambrose, 2011). 
Structural MRI studies in FM patients are fewer. Most used voxel-based 
morphometry (VBM) to assess gray matter density / volume (Kuchinad et al., 2007; 
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Schmidt-Wilcke et al., 2007; Luerding et al., 2008; Burgmer et al., 2009; Hsu et al., 
2009; Robinson et al., 2011) or VBM with another MRI modality such as diffusion 
weighted imaging (Lutz et al., 2008) or imaging technique like positron emission 
tomography (Wood et al., 2009). Diffusion weighted imaging was used alone in an early 
study (Sundgren et al., 2007) and recently a cortical thickness analysis was done in 
conjunction with functional connectivity of stimulus-evoked BOLD measurements 
(Jensen et al., 2013) as well as a multi-modal MRI using both functional and structural 
imaging in FM patients (Ceko et al., 2013). These studies will be described in more 
details in the respective chapters on diffusion weighted (chapter 2) and high-resolution 
anatomical imaging (chapter 3). 
Rationale for investigating brain structural characteristics of fibromyalgia 
As described above, structural brain characteristics in FM patients have been 
explored mostly via VBM assessment of gray matter volume / density measurements. 
These measurements are capable of showing brain structural differences between 
chronic pain patients and controls, as shown in a recent meta-analysis (Smallwood et 
al., 2013). Neuroplasticity has long been associated with chronic pain, however it was 
unknown if brain structural changes were a cause or consequence of it (May, 2008). 
Longitudinal studies reporting pre- and post-treatment data of patients suffering from 
chronic pain secondary to osteoarthritis (Rodriguez-Raecke et al., 2009; Gwilym et al., 
2010) and low back pain (Seminowicz et al., 2011) showed that most of the brain 
structural abnormalities detected were reversible. This finding is supported by a study 
that compared older non-clinical subjects divided into 3 groups: controls, ongoing pain 
and past pain (stopped > 12 months) (Ruscheweyh et al., 2011). The ongoing pain 
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group showed gray matter decreases compared to controls, while the past pain group 
did not. Other interesting recent findings in healthy controls were that lack of habituation 
to noxious stimuli is associated with gray matter reductions (Stankewitz et al., 2013) and 
a negative association between pain ratings and gray matter density (Emerson et al., 
2014). These studies show that other variables besides patient status might explain 
gray matter morphometric differences, and those must be taken into account when 
interpreting results from clinical samples. 
Diffusion MRI can probe tissue micro-structure in a non-invasive manner, 
providing unique brain information on the microscopic scale in both health and disease 
states (Le Bihan, 2003). Two early studies reported DWI data from FM patients 
(Sundgren et al., 2007; Lutz et al., 2008). These pioneering studies, while valuable, 
were limited by the available technology, i.e., use of 1.5 Tesla MR scanners, low 
number of encoding directions, manually drawn ROIs, and focus on only 2 diffusion 
metrics (apparent diffusion coefficient and fractional anisotropy). Current MR technology 
and software packages for neuroimaging analyses allow a more extensive approach to 
DWI, for both data acquisition (higher signal-to-noise ratio from higher magnetic fields, 
greater number of diffusion-encoding directions, cardiac-gate acquisition, brain 
probabilistic atlases for region of interest selection among others) and processing 
(several available software packages for DWI data analysis) (Hasan et al., 2011; Soares 
et al., 2013). 
From the aforementioned, it seems possible that the brain structural 
characteristics in FM have been underexplored. In order to address this gap of 
knowledge, this dissertation project aimed at developing a comprehensive assessment 
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of brain micro- and macro-structural characteristics in FM patients using reference data 
from healthy, painfree control subjects. 
Objectives 
The objectives of this dissertation were: 
• To recruit a relatively large sample of FM patients and age- and sex-
matched controls and perform a detailed characterization based on 
demographic attributes, clinical measures and psychosocial instruments; 
• To determine global and regional micro-structural brain tissue 
characteristics using diffusion weighted imaging for those subjects; and 
• To do a comprehensive assessment of brain macro-structural features for 
both FM and control subjects using high-resolution anatomical imaging, 
which includes brain volume estimation, gray matter assessment, 
subcortical structures segmentation and volumetric analysis, and 
measurement of brain cortical and subcortical characteristics. 
Methods overview 
In this section, an overview of the methods used in this dissertation will be 
provided. All subjects recruited as described below participated in the studies reported 
in subsequent chapters, and their data (demographic characteristics, clinical measures, 
questionnaires scores) were used accordingly where appropriate for particular analyses 
as outlined in each chapter. 
Subjects 
Study participants consisted of 30 female FM patients and 30 age-matched 
healthy females. Participants were recruited by referrals from local rheumatologists and 
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through advertisements in the local community. A calibrated examiner assessed all 
subjects using the 1990 ACR classification criteria (Wolfe et al., 1990). Additionally, FM 
patients were also assessed using the ACR 2010 diagnostic criteria (Wolfe et al., 2010). 
Inclusion criteria for FM patients were: 1) female patients with age between 18 and 64 
years; and 2) fulfillment of the ACR 1990 FM classification criteria. Exclusion criteria for 
all subjects were: 1) significant hearing loss (determined by self-report and hearing 
screening) or the use of hearing aid; 2) medical conditions capable of worsening 
physical functional status independent of FM (e.g., morbid obesity, cardiopulmonary 
disorders, uncontrolled hypertension, uncontrolled endocrine or allergic disorders, 
disorders of vestibular system, renal disorders, seizures, psychiatric disorders requiring 
hospitalization ≤ 6 months, cancer within the last 2 years or current chemotherapy / 
radiation treatment); 3) current substance abuse; 4) pregnancy; or 5) any typical MRI 
contraindication, including claustrophobia. Patients taking opioid medications on a 
regular basis were also excluded. Participants were allowed to continue with their 
regular medication regimen; however, they were asked to avoid any analgesic 
medication 24 hours prior to the MRI session. Healthy controls reported no current 
chronic pain condition at the time of enrollment. Informed consent was obtained from all 
study participants for procedures approved by the Institutional Review Board at the 
University of North Carolina (UNC) at Chapel Hill.  
Data collected for this dissertation were part of a larger project that included 
psychophysical and behavioral testing done for all subjects in separate visits, in addition 
to a single MRI scanning session where multi-modal MRI data were collected (stimulus-
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evoked BOLD, resting-state BOLD, resting-state arterial spin labeling) in addition to the 
herein reported diffusion weighted and high-resolution T1-weighted anatomical imaging. 
Demographic characteristics and clinical measures 
Age, weight and height were collected from all subjects by self-report. We 
assessed handedness by using the scale proposed by Chapman and Chapman 
(Chapman and Chapman, 1987). It consists of 13 items that describes several specific 
activities where the participant must answer, “which hand you ordinarily use for each 
activity” (1-right, 2-either, 3-left). It yields a summed score that can range from 13 
(completely right-handed) to 39 (completely left-handed). We used the cut-off ranges 
suggested by those authors: right-handed = 13-17, left-handed = 33-39, ambilateral = 
18-32. 
FM patients reported the average pain level in the past 2 weeks using a 0-100 
numerical rating scale (NRS; anchors: 0 = No pain, 100 = Most intense pain imaginable). 
They were also asked to report the time in years since the onset of their widespread 
pain. At the day of the MRI scanning, all participants were asked to rate their current 
pain level using the 0-100 NRS, and they also rated separately their current pain 
intensity and pain unpleasantness using the 0-20 Gracely’s box scales (Gracely et al., 
1978). 
Questionnaires 
Measures of affective distress 
Depressive symptoms were measured using the Beck Depression Inventory 
(BDI) (Beck et al., 1961). The BDI is a 21-item questionnaire that measures symptoms 
and attitudes related to depression by rating their intensity between 0-3, and it has been 
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extensively validated (Beck et al., 1988). The sum of all items gives the total score, 
which ranges between 0-63. 
Level of trait anxiety was measured using the State-Trait Anxiety Inventory (STAI 
Y2) (Spielberger et al., 1983). Participants rated how they generally feel by answering 
each of the 20 items using a 4-category scale (1 = Almost Never; 2 = Sometimes; 3 = 
Often; 4 = Almost Always). The total score is the sum of all items scores, ranging from 
20 to 80. 
Measure of psychosocial stress 
The perceived stress scale (PSS) is 10-item scale that assesses the perception 
of stress (Cohen et al., 1983). Participants indicate for each item how they felt or 
thought in the previous month using a 5-category scale (Never, Almost Never, 
Sometimes, Fairly Often, Very Often). The total perceived stress score is the sum of the 
weights of all items (0-4), ranging from 0 to 40. 
Measure of coping 
The Coping Strategies Questionnaire-Revised (CSQ-R) is a revised version of 
the originally proposed CSQ (Rosenstiel and Keefe, 1983), and it is composed of 27 
items that are related to the strategies used by individuals to cope with pain. For each 
item, the participants indicate how frequent they engaged in a particular coping strategy 
using a 7-category numerical scale (anchors: 0 = Never do that; 6 = Always do that). Six 
subscales measuring different strategies used by the individual are derived: 
catastrophizing (range for the subscale items sum = 0-36), distraction (0-30), ignoring 
pain (0-30), distancing from pain (0-24), coping self-statements (0-24), and praying (0-
18). 
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Measure of somatic awareness 
Somatic awareness, or the general tendency to endorse physical symptoms, can 
be estimated through the Pennebaker Inventory of Limbic Languidness (PILL) 
(Pennebaker, 1982). This questionnaire is composed of 54 items that describes 
physical symptoms and the participant answers how often each occur in a 5-category 
scale (Never or almost never have, Less than 3 or 4 times per year, Every month or so, 
Every week or so, More than once every week). The PILL summary score was derived 
by summing the scores for each of the 54 items. 
Additional questionnaires (pain descriptors, sleep quality) 
The short-form McGill pain questionnaire (SF-MPQ) provides information on the 
dimensions of clinical pain (Melzack, 1987). The version used in the present study 
includes the 15 pain descriptors that the participant must rate the intensity in a 4-
category scale (None, Mild, Moderate, Severe). The pain descriptors can be divided in 
sensory or affective, and by summing the respective items two scores are formed 
(range for sensory score = 0-33; affective score = 0-12). 
Sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI) 
(Buysse et al., 1989), which has 19 questions where the participant reports different 
aspects of their sleep in the last month. These 19 items are then combined in 7 
component scores (Subjective sleep quality, Sleep latency, Sleep duration, Habitual 
sleep efficiency, Sleep disturbances, Use of sleep medication, Daytime dysfunction) 
where each ranges from 0 (no difficulty) to 3 (severe difficulty). A global PSQI score can 
be derived by summing all components, ranging from 0 to 21 according to the degree of 
severity in each area as described by the components’ scores. 
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MRI scanning session 
All participants underwent a single MRI scanning session at the Biomedical 
Research Imaging Center at UNC-Chapel Hill, using its 3-Tesla Trio Siemens MR 
scanner with a 12-channel head coil. Prior to entering the scanner room participants 
filled the 0-100 NRS for current pain and the Gracely’s box scales for pain intensity and 
unpleasantness, and they were instructed on what to expect during the scanning (high 
level of noises and vibrations, avoidance of head motion during imaging acquisition, 
ability to communicate with investigators at any time if needed). Once in the scanner 
room, participants were fitted comfortably on the scanner bed with a leg support pillow. 
Their head was padded with foam pads to minimize movements and ear muffs were 
used for hearing protection. A vitamin E capsule was attached to the right temple of the 
participants’ head to avoid right-left ambiguities during imaging data processing and 
analysis. Physiological monitoring was done by fitting a peripheral pulse oximeter to the 
participant’s left index finger and a respiration belt. Communication with participants 
was established via intercom in between imaging runs. After all imaging data were 
acquired, participants were removed from the scanner and debriefed for any discomfort 
or problems during the scanning. 
Details for diffusion weighted and high-resolution anatomical imaging acquisition 
parameters will be offered in the respective chapters. 
Statistical analysis 
Results are reported in the format of mean ± SD, unless otherwise stated. Data 
distribution was checked via histograms and tested using the Kolmogorov-Smirnov test. 
Data fitting the normal distribution were tested for between-group comparisons using 
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the independent samples t-test (2-tailed). Non-normally distributed data were tested 
using the independent samples Mann-Whitney U test (2-tailed). All statistical tests were 
considered significant at p < 0.05. 
Results 
Demographic characteristics and clinical measures 
Subjects’ demographic characteristics and clinical measures details are offered 
in Table 1.1. We used the ACR 1990 FM classification criteria as the inclusion criterion 
for the patient group, and found discordance in 3 patients that met the classification but 
did not fit the ACR 2010 FM diagnostic criteria. As a result of the matching procedure, 
the participants’ age did not significantly differ between groups (FM patients mean age ± 
SD: 42.9 ± 12.2 years; controls: 44.2 ± 11.7 years; p = 0.675), with a wide range 
observed (FM patients minimal and maximum age: 23 - 63; controls: 23 - 61). Body 
mass index (BMI) was calculated for all subjects in units of kg/m2 and it was significantly 
different between groups, with FM patients and controls mean BMI at the opposite ends 
of the range for the “overweight” category (FM: 29 ± 6.8; controls: 25.6 ± 5.5; p = 0.037) 
(http://www.nhlbi.nih.gov/health/public/heart/obesity/lose_wt/risk.htm). Handedness was 
similar between groups, with the major difference being in the “right” and “ambilateral” 
categories. As noted by its proponents, the cut-off ranges are “necessarily arbitrary” 
(Chapman and Chapman, 1987). Using the individuals’ scores and assigning right-
handedness to a range of 13-25 and left-handedness to 26-39, FM patients and controls 
included 27 and 28 right-handed participants respectively which was not significantly 
different (p = 0.285). 
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The duration of widespread pain for FM patients was 11.4 years (± 9.3) on 
average, with a range of 1 to 40 years. Average pain in the last 2 weeks was a minimum 
of 25 and a maximum of 85 using the 0-100 NRS (mean ± SD: 57.1 ± 16.3). At the day 
of MRI scanning, FM patients rated their current pain (0-100 NRS: 47.8 ± 19), current 
pain unpleasantness (0-20: 8.2 ± 2.9) and intensity (0-20: 9.7 ± 3.4) significantly 
different than controls (p < 0.0001) as expected. 
Questionnaires 
Measures of affective distress, psychosocial stress, coping, and somatic 
awareness were markedly higher for FM patients compared to controls (Table 1.2). 
Depressive symptoms and trait anxiety as measured by BDI and STAI Y2, respectively, 
were significantly greater for the patient group (p < 0.0001). Psychosocial distress as 
perceived by participants was highly significantly different between groups (FM patients: 
18.8 ± 8.3; controls: 9.7 ± 6; p < 0.0001). From the coping strategies measured by the 
CSQ-R, only catastrophizing (p < 0.0001) and ignoring pain (p < 0.017) reached 
statistical significance for group differences. Somatic awareness, derived from PILL 
scores, was significantly greater for FM patients (153.8 ± 36.7) compared to controls 
(84.9 ± 20.8) (p < 0.0001). 
As expected, scores for sensory and affective pain descriptors were much 
greater for the patient group (p < 0.0001 for both). Finally, moderately reduced sleep 
quality was present for the FM patients according to the PSQI global score (10.9 ± 3.4) 
but not for controls (3.2 ± 2) (p < 0.0001). 
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Discussion 
The present subject sample was well characterized using several demographic 
characteristics and clinical measures, with results reported here consistent with 
previous literature including BMI (Ursini et al., 2011; Timmerman et al., 2013). Many of 
the psychosocial measures described have been used in neuroimaging studies of FM 
patients (Schmidt-Wilcke et al., 2007; Jensen et al., 2010; Burgmer et al., 2011; Jensen 
et al., 2013). Assessment of sleep quality in FM using the PSQI has been performed 
previously, with similar results (Osorio et al., 2006; Munguia-Izquierdo and Legaz-
Arrese, 2011). Given the use of validated classification criteria for FM, the 
characterization of our subjects using different dimensions of clinical and psychosocial 
measures and also the relatively large sample size, the results reported here and 
subsequent chapters are likely representative of the FM patient population. 
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Table 1.1. Demographic characteristics and clinical measures. 
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Table 1.2. Questionnaires scores. 
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CHAPTER 2: ASSESSMENT OF BRAIN MICRO-STRUCTURAL 
CHARACTERISTICS OF FIBROMYALGIA PATIENTS USING DIFFUSION 
TENSOR IMAGING 
Introduction 
Augmented pain and sensory processing is considered a main feature of 
fibromyalgia (FM) presentation. At least part of its putative mechanisms likely originate 
from the central nervous system (CNS) with several lines of evidence supporting this 
view (Clauw, 2009), including central sensitization mechanisms such as the “wind-up” 
phenomenon and impaired pain modulatory systems being described in FM patients. 
Neuroplastic brain changes in chronic pain is well described (Latremoliere and Woolf, 
2009; Siddall, 2013), and it is corroborated by neuroimaging studies (Seifert and 
Maihofner, 2011). Neuroplasticity within the brain is one putative mechanism in FM and 
concurs with a role for the CNS in its pathophysiology, with functional, neurochemical, 
and structural brain abnormalities in patients when compared to controls being 
described (Gracely and Ambrose, 2011). 
Recent studies of FM using magnetic resonance imaging (MRI) modalities have 
focused on macro-structural brain characteristics, with the most common approach 
being voxel-based morphometry (VBM). Two studies investigated micro-structural 
features of the brain in FM patients using diffusion MRI (Sundgren et al., 2007; Lutz et 
al., 2008). Their results only partially overlapped with findings of white matter (WM) 
abnormalities in the right thalamus. The later study reported several other WM 
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dissimilarities between FM patients and controls, and attributed these discordant results 
between both studies to methodological differences (Lutz et al., 2008). These 
pioneering studies did not benefit from recent methodological improvements in diffusion 
MRI, including advancements in MR scanners technology, computational methods and 
availability of dedicated software packages (Hasan et al., 2011; Soares et al., 2013). 
Recently a study using multi-modal MRI including diffusion reported regional WM 
abnormalities in FM patients relative to age-matched controls (Ceko et al., 2013) 
The main goal of the present study was to determine brain micro-structural 
characteristics in FM patients, and assess potential WM abnormalities using age-
matched controls as reference. Diffusion MRI allows this in a non-invasive manner, by 
measuring water molecule diffusion within the brain tissues. It is a versatile MRI 
modality not only for research but also for clinical uses, e.g., detection of acute brain 
ischemia (Sundgren et al., 2004). Our main focus was to assess micro-structural 
features of: i. WM tracts using tract-based spatial statistics (TBSS), and ii. Whole brain 
and pain-related regions of interest (ROI). We hypothesized that FM patients would 
present both global and regional brain WM abnormalities when compared to matched 
controls, including pain-related areas of the brain. 
Methods 
Imaging acquisition parameters 
Subjects were accommodated in the MRI scanner as described in chapter 1, 
methods section. The diffusion weighted imaging (DWI) data acquisition consisted of a 
single run using an echo-planar imaging sequence (repetition time (TR) ~ 8,000 ms; 
echo time (TE) = 83 ms; field of view = 256 mm; 2 x 2 x 2 mm3 voxels; parallel imaging 
 31 
factor = 2 (GRAPPA)) acquired along 42 non-collinear, non-coplanar directions (b = 
1,000 s/mm2). Two dummy volumes were acquired and discarded to allow the 
longitudinal magnetization to reach a steady state prior to data acquisition. Seven non-
diffusion weighted images (B0; b = 0 s/mm2) were acquired at equidistant points 
throughout the acquisition at a ratio of one B0 image for every seven diffusion weighted 
images – within the range of suggested optimum ratios for assumptions of isotropic and 
anisotropic tensors (Jones et al., 1999; Alexander and Barker, 2005). A total of 68 slices 
oriented to the axial plane (no gap) were collected to ensure whole brain coverage (from 
vertex to second cervical spinal process). The image sequence was synchronized to the 
subject’s cardiac cycle via a pulse oximeter signal with no delay (cardiac gating), 
avoiding data acquisition when the brain is susceptible to cardiac pulsatility which can 
severely corrupt diffusion weighted data (Jones and Leemans, 2011). We also acquired 
fieldmap images (TR = 800 ms; TE1 = 4.92 ms, TE2 = 7.38 ms; field of view = 256 mm; 
4 x 4 x 2 mm3 voxels; 68 slices) immediately prior to the DWI data acquisition, in order 
to correct for geometric distortions secondary to magnetic field inhomogeneities 
(Jezzard, 2012). 
Diffusion tensor imaging, tensor model and related metrics 
Diffusion is a physical process, where molecules present a constant random 
thermal motion at temperatures above absolute zero. This was described by Robert 
Brown in 1828 (Jones, 2009), thus this is also known as “Brownian motion”. Despite its 
trajectory being a “random walk” in 3D space, Einstein showed in 1905 that one 
characteristic of diffusion could be characterized if a large enough number of molecules 
are free to diffuse: the diffusion coefficient D (in units of mm2/s) is proportional to the 
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mean square displacement of all molecules, 〈∆r2〉, divided by the number of dimensions, 
n, and the diffusion time, t (Alexander et al., 2007; Jones, 2009): 
• D = 
!∆!!!!!∆!  
At body temperature (37 Cº) a cube of water of an approximate volume of 2.5 
mm3 present a diffusion coefficient of 3 x 10-3 mm2/s, thus following an observation time 
of 30 ms water molecules would have displaced approximately 25 µm in all directions 
on average (Jones, 2009). In the brain, however, water molecules are not free to diffuse 
as there are many barriers including cellular membranes, myelin sheaths and 
cytoskeleton macromolecules. Therefore diffusion within brain tissues is approximately 
four times smaller compared to “free” diffusion, and it is thus called apparent diffusion 
coefficient (ADC) (Jones, 2009). 
Diffusion has contrasting features in gray matter (GM) and WM. In the former 
diffusion occurs in all directions due to a convoluted tissue orientation (isotropic), while 
in the latter there is a high directionality component of tissue orientation from the 
bundling of axonal fibers, i.e., anisotropy. Thus the diffusion magnitude within the brain 
WM as measured by the ADC will depend on the direction used for measurement, 
making a single ADC measurement insufficient to fully characterize water diffusion in 
WM. Where diffusion is isotropic (GM, cerebral spinal fluid (CSF)), the probability of the 
mean displacement of water molecules can be represented by a diffusion sphere; for 
anisotropic diffusion however, when diffusion has a preferential main direction such as 
within WM, this is better described by a diffusion ellipsoid (Figure 2.1 A). 
In diffusion MRI magnetic gradients are applied in multiple directions to allow the 
characterization of diffusion within the brain parenchyma. Using a diffusion weighting 
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factor (b-value), a brain image composed of several volume elements (voxels) can be 
acquired by imposing magnetic gradients on a particular direction. Non-diffusion 
weighted images where the b-value is zero are also acquired. By measuring the water 
displacement in multiple directions from the diffusion-weighted and non-diffusion 
weighted images the diffusion can be quantified in a voxelwise manner. 
In order to adequately represent diffusion in an anisotropic medium such as WM, 
data from diffusion MRI can be modeled in a voxel-by-voxel basis using a diffusion 
tensor (Basser et al., 1994a; Basser et al., 1994b), i.e., diffusion tensor imaging (DTI). 
The diffusion tensor D is a 3 x 3 symmetric matrix, where the diagonal elements 
represent diffusivities along three orthogonal axes (Dxx, Dyy, and Dzz) and correlations 
between those are represented by the symmetric off-diagonal elements (Dxy = Dyx, Dxz = 
Dzx, and Dyz = Dzy): 
 
          D = 
 
 
 
The diffusion ellipsoid can be described by applying a mathematical procedure to 
the diffusion tensor matrix, i.e., diagonalization, so that its internal frame of reference (x’, 
y’, z’) matches the principal axes of the measurement frame (x, y, z). In such case, all 
off-diagonal elements are zero and the orientation of the ellipsoid main axes is given by 
eigenvectors (ε1, ε2, ε3), with the orientation of the tensor depicted by the principal 
eigenvector (ε1) – its direction is assumed to be parallel to the dominant fiber orientation 
within the voxel being measured. The degree of diffusion along the eigenvectors is 
given by the respective eigenvalues: λ1, λ2, λ3 (corresponding to Dxx, Dyy, and Dzz); thus 
Dxx Dxy Dxz 
Dyx Dyy Dyz 
Dzx Dzy Dzz 
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the displacement within the ellipsoid in each axis is scaled to the square root of the 
corresponding eigenvalue (according to Einstein’s formula) (Winston, 2012). The 
eigenvalues are, by definition, sorted according to their magnitude, i.e., λ1 > λ2 > λ3 
(Figure 2.1 A). 
From the eigenvalues determined from the tensor model it is possible to derive 
scalar measurements that allow simplification of the diffusion data (as opposed to have 
brain images where each voxel contains a 3 x 3 matrix). These quantitative parameters 
were originally proposed by Basser and Pierpaoli in 1996 (Basser and Pierpaoli, 1996), 
and they include: 
• Trace, which measures the magnitude of diffusion: 
o Sum of the three eigenvalues: λ1 + λ2 + λ3 
• Mean diffusivity (MD), the mean diffusion across all three axes: 
o Average of the three eigenvalues :(λ1 + λ2 + λ3) / 3 
• Fractional anisotropy (FA) is an anisotropy index, that measures the 
fraction of the tensor that can be attributed to anisotropy parallel to the 
orientation of the main fiber tract (in the formula, L = λ): 
o FA = !!    (!!!!")!!  (!!!!")!!  (!!!!")!!!!!  !!!!  !!!  
Both trace and MD have units of mm2/s, while FA is dimensionless and 
normalized so that its values range from 0 (isotropic diffusion) to 1 (anisotropic diffusion, 
i.e., constrained along one axis). 
MD is known to have remarkably similar values across GM and WM (similarly to 
the ADC) - around 7 x 10-4 mm2/s (Winston, 2012) - and show increased values in areas 
with local inflammation / edema (Alexander et al., 2007) while increased cellularity 
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(Gauvain et al., 2001) and cellular swelling (Benveniste et al., 1992) reduces MD. FA 
values for healthy WM have a peak close to 0.3 (Alexander et al., 2007), with values 
around 0.2 for cortical GM, 0.2-0.4 in deep GM and a wider range in WM (circa 0.45 in 
subcortical WM to about 0.8 in the corpus callosum) (Beaulieu, 2009). Given such 
variability for FA values across the brain it becomes clear that only similar brain regions 
can be compared using this measure, i.e., comparing the FA from area “X” to area “Y” is 
meaningless to infer underlying micro-structural differences such as axonal density or 
degree of myelination (Beaulieu, 2009). It has been reported that the parallel disposition 
of WM bundles is key for diffusion anisotropy (Alexander et al., 2007), due to the 
presence of axonal membranes. Myelination has a secondary modulatory role for FA, 
as unmyelinated fibers also present anisotropic diffusion and animal models of 
dysmyelination (failure to form normal myelin) showed an average FA reduction of only 
15% (range 0-32%) (Beaulieu, 2009). Hence several factors can impact the FA value 
measured within a voxel including axonal count and density, myelination, fiber 
organization, and crossing fibers (Winston, 2012). 
It is important to note that FA does not describe the tensor shape or distribution 
in its entirety, as different eigenvalue combinations can result in similar FA values. Thus 
studies have used the eigenvalues separately or in combination to provide a more 
specific understanding of WM micro-structure (Alexander et al., 2007; Winston, 2012): 
• Axial diffusivity (AD) is the diffusivity parallel (longitudinal) to the main 
axis of diffusion: 
o Represented by λ1 
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• Radial diffusivity (RD) is the diffusivity perpendicular (orthogonal) to the 
main axis of diffusion: 
o Average of the two eigenvalues orthogonal to λ1: (λ2 + λ3) / 2 
These two measures, as they are derived from the eigenvalues directly, also 
have units of mm2/s. AD is considered a marker for axonal damage (reduced AD ≈ 
axonal degeneration), while increases in RD reflects myelin degradation (Alexander et 
al., 2007; Winston, 2012). 
Lastly, the mode (MO) of anisotropy can specify the geometric shape of the 
ellipsoid (Ennis and Kindlmann, 2006) (in the formula, L = λ): 
• MO = !!  !  !!  !  !!(!!!!")!!  (!!!!")!!  (!!!!")! ! 
Its values range from -1 to +1 (dimensionless), describing a tensor that is disc-
shaped (planar anisotropy) to one that is a tubular (linear anisotropy) respectively 
(Smith and Kindlmann, 2009; Winston, 2012). MO values closer to -1, indicating a disc-
shaped (oblate) tensor where λ1 ≈ λ2, is suggestive of crossing fibers while values 
closer to +1 (prolate tensor) indicates primarily a single dominant fiber (λ2 ≈ λ3) (Fig. 2.1 
B). MO is orthogonal (mathematically independent) to FA, and it can provide important 
additional information about diffusion within the brain. This importance can be 
appreciated when assessing FA measurements, as brain areas with crossing WM tracts 
(lower MO values) will present lower FA values in the absence of any WM abnormality 
(Alexander et al., 2007). 
DWI preprocessing steps 
All processing steps for diffusion weighted images were done using the Oxford 
Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB) software 
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library (FSL v. 5.0.5) (Smith et al., 2004; Jenkinson et al., 2012) 
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki). DWI and fieldmap images were reoriented to the 
Montreal Neurological Institute (MNI) brain template using the FSL tool “fslreorient2std”, 
and then loaded into the visualization tool “FSLview” to be visually checked for any 
obvious artifacts. Eddy current and motion artifact correction was done using the FMRIB 
Diffusion Toolbox (FDT), followed by application of the rotational component of the 
transformation for each volume to the gradient direction encoding vectors. The resulting 
eddy current and motion corrected DWI images were visually inspected. Individual brain 
masks were derived from the first B0 image using the Brain Extraction Tool (BET) (Smith, 
2002). Fieldmap images were processed using the FSL tool “fsl_prepare_fieldmap”, and 
then used to correct geometric distortions in the DWI images as implemented by FSL’s 
FUGUE, and the resulting output was visually inspected for artifacts. 
Finally, a diffusion tensor model was estimated from the undistorted DWI images 
using weighted linear least-squares regression as implemented by FDT (Behrens et al., 
2003). An image of the sum of squared error was also produced by FDT and it was 
visually checked for artifacts, as well as the calculated FA, MD, AD and MO parametric 
maps. RD images were calculated as the average of the maps for the two radial vectors 
eigenvalues (λ2, λ3) using the FSL tool “fslmaths”. 
Tract-based spatial statistics 
Tract-Based Spatial Statistics (TBSS) (Smith et al., 2006) were used to carry out 
voxelwise analysis of the FA data for FM patients and controls. TBSS processing steps 
include: 1) non-linear registration of the FA maps to a 1 x 1 x 1 mm3 standard space FA 
image as target (FMRIB58_FA: high-resolution average of 58 FA maps from healthy 
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male and female subjects aged between 20-50 
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FMRIB58_FA)); 2) a mean FA image derived from all 
subjects was created, then thinned to represent the center of the major WM tracts 
common to all subjects, i.e., a mean WM skeleton image; 3) the mean FA skeleton was 
thresholded at 0.2 to include FA values with acceptable cross-subject variability, then 
each individual’s normalized FA map was projected into the skeleton resulting in a 4D 
image file containing the skeletonized FA data for all subjects. 
Non-FA images of the additional DTI metrics (AD, MD, RD, MO) were also 
processed using TBSS. Each of the non-FA images was registered into standard space 
by applying the non-linear registration calculated for FA images, then projected onto the 
original mean FA skeleton. Therefore for each non-FA DTI metric a 4D skeletonized 
image was generated, where voxels in the same spatial location contain each of those 
metrics values respectively. 
Statistical analyses 
TBSS analysis (voxelwise) 
A between-group permutation-based nonparametric t-test (Nichols and Holmes, 
2002) using age as a covariate of no interest was done, using the 4D skeletonized 
mean FA image as input for the FSL tool “randomise” with 5,000 permutations and 
using the threshold-free cluster enhancement option. This option allows the detection of 
cluster-like formation(s) of significant voxels with no arbitrary thresholding while 
controlling for family-wise error rate across space, therefore correcting for multiple 
comparisons (Smith and Nichols, 2009). This way, voxelwise statistics reported here 
were tested for significance at p-value < 0.05, corrected. 
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The WM skeleton is thin (few voxels wide) thus hard to visualize when overlaid 
onto a brain image, therefore we used the FSL tool “tbss_fill” to thicken the skeleton 
areas with significant group differences for enhanced visualization. Location of 
significant differences between groups were identified using FSLview and the built-in 
anatomical atlases (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases), as well as a MRI-based 
atlas of human WM (Oishi and Crain, 2011). 
Whole brain, WM skeleton and pain-related region of interest analyses 
To perform between-group comparisons for the whole brain and WM skeleton, 
each DTI parametric map was averaged across the whole brain and across all voxels 
within the WM skeleton for each subject. 
Additionally, a region of interest (ROI) analysis was done based on a priori brain 
anatomical regions that are commonly activated following noxious stimulation (Peyron 
et al., 2000; Apkarian et al., 2005), including a subcortical structure (thalamus) as well 
as cortical areas including the primary (SI) and secondary (SII) somatosensory cortices, 
the insula, and the anterior cingulate cortex (ACC). The inferior parietal lobule (IPL) was 
also included, which is a cortical area that integrates somatosensory and visual inputs 
and was activated following noxious pressure stimulus to the thumbnail during stimulus-
evoked functional MRI in the participating FM patients and controls (unpublished data). 
A binary mask image was generated for each of those ROIs using three probabilistic 
atlases available in FSL (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases): the Harvard-Oxford 
cortical and subcortical atlases (Desikan et al., 2006) and the Jülich histological atlas 
(Eickhoff et al., 2006). From the Harvard-Oxford atlases ROI masks for right and left 
thalamus and insula were derived, while the ACC mask was built as a single region; 
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right and left SI, SII, and IPL were derived from the Jülich atlas. Since the cortical ROIs 
were constructed from probabilistic atlases moderately thresholded at p = 0.25, they 
encompassed voxels beyond the cortical mantle and included WM voxels within it, a 
method used previously for DTI measurements (Stein et al., 2012). These WM voxels 
preferentially include afferent/efferent fibers associated with the cortical region proximal 
to it (Salat et al., 2009a). We extracted the mean for each DTI metric across all voxels 
within each ROI, as well from the WM skeleton voxels within it (Figure 2.2). 
Between-group differences were assessed using analyses of covariance with 
age as a covariate of no interest. All statistical tests were done using SPSS v. 18, with 
significance thresholding of p < 0.05. 
We also assessed associations of DTI metrics measured in the whole brain and 
ROIs with subject’s clinical measures and psychosocial questionnaire scores using the 
Pearson’s correlation coefficient “r”. Correlations with p-value < 0.01 were considered 
significant. 
Results 
Subjects demographics characteristics, clinical measures and questionnaires 
A full description of the FM patients and controls is presented in chapter 1, 
results section. 
TBSS analysis (voxelwise) 
Between-group WM skeleton-based comparisons, corrected for age, identified 
several clusters where FM patients had lower FA compared to controls (Table 2.1; 
Figures 2.3 to 2.6). The largest cluster (2,305 voxels) included the right corticospinal 
tract and WM adjacent to the right SI and the primary motor cortex (M1), and several 
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clusters summing 2,729 voxels were localized within the corpus callosum, including the 
genu, body and splenium. Two clusters were localized in the anterior limbs of the 
internal capsule (IC) and anterior corona radiata, one on the left (709 voxels) and 
another on the right (431 voxels) side. The left corticospinal tract, and WM adjacent to 
the left SI and M1 were part of another cluster with 568 voxels. Other clusters were 
localized in the inferior fronto-occiptal, inferior longitudinal and superior longitudinal 
fasciculi (1,984 voxels), while 140 voxels were localized deep within WM. No significant 
cluster was found for FM having increased FA compared to controls.  
Group differences for other DTI metrics included significant increases of RD 
(10,356 voxels) and MD (10,805 voxels) for the patient group, while MO showed 
reductions for patients in a limited spatial distribution (1,526 voxels) – see description 
below. No group differences for AD were found in either direction. 
Figures 2.3 to 2.6 show the spatial distribution of significant clusters in which FM 
patients had lower FA values compared to controls (left panel), and where FM patients 
had greater RD values (right top panel) and greater MD values (right bottom panel) 
(green = WM skeleton; red = FA, blue = RD, purple = MD, yellow = overlap between FA 
and RD / MD in the right-sided panels). Figure 2.3 and 2.4 show sagittal and axial views 
respectively of significant FA differences in the corpus callosum (left panel); overlap of 
FA and RD are noticeable in the genu and body, and also anterior limbs of IC (right top 
panel) while MD mostly overlaps FA in the genu and right anterior limb of IC (right 
bottom panel). Corticospinal tracts had significant reduction of FA in patients bilaterally 
(Figure 2.5, left panel), with MD differences overlapping both sides while RD showed a 
similar pattern however slightly less distributed (right bottom and top panels, 
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respectively). WM tracts close to SI and M1 with reduced FA in patients are shown in 
Figure 2.6 left panel, with the tracts showing overlap of RD and MD differences depicted 
on the right top and bottom panels respectively. 
Significantly reduced MO in patients as compared to controls was spatially 
limited compared to the other DTI metrics’ parametric maps, with differences mostly 
over the genu, body and splenium of corpus callosum (765 voxels), and parts of the 
corona radiata (761 voxels) (data not shown). No increases of MO for patients 
compared to controls were significant. 
Whole brain, WM skeleton and pain-related region of interest analyses 
Comparing DTI metrics across the whole brain showed no group differences for 
FA (p = 0.32), however AD and MD were significantly reduced for FM patients 
compared to controls (p = 0.023 and p = 0.037 respectively) while RD approached 
significance (p = 0.051) (Figure 2.7). For measures within the WM skeleton no 
significant differences were found, although FA reduction in patients compared to 
controls was close to significance (p = 0.065). 
ROI analyses revealed an interesting pattern (Table 2.2 and 2.3). When 
comparing DTI metrics across all voxels within each ROI (non-skeletonised), no 
significant differences were found for FA (0.093 < p < 0.984) but the left and right SI in 
FM patients had significantly reduced AD (p = 0.034 and p = 0.004 respectively), RD (p 
= 0.045; p = 0.005) and MD (p = 0.041; p = 0.004) compared to controls. The right 
inferior parietal lobule also showed a similar reduction for patients but did not reach 
significance (p-value for AD = 0.052; RD = 0.066; MD = 0.06) (Table 2.2). 
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Assessing metrics for WM skeleton voxels within each ROI showed more varied 
differences (Table 2.3). For WM skeleton FA and RD, both left and right SI showed 
significant differences in patients compared to controls (reduced FA in left and right SI: 
p = 0.002 and p = 0.001 respectively; increased RD: p = 0.004 and p = 0.011) while for 
MD only left SI showed a significant increase (p = 0.016). Compared to controls, FM 
patients showed significant reductions in AD, RD and MD in the left insula (all at p < 
0.001). 
Association of DTI metrics with clinical and psychosocial measures 
When assessed in the whole brain (non-skeletonised), DTI metrics showed 
significant correlations with age in FM patients (r for FA = -0.54, AD = 0.49, RD = 0.56; 
MD = 0.54) and controls (AD = 0.65; RD = 0.68; MD = 0.67), indicating that increased 
age is associated with reduced FA and increased AD, RD, and MD. Within the WM 
skeleton, negative correlations between age and FA (r = -0.47) and between BMI and 
AD, RD, and MD were found only for patients (-0.68 < r < -0.47) (Table 2.4), thus 
increased BMI in patients is correlated with decreases in AD, RD and MD. No 
associations for DTI metrics and pain characteristics were found, and no psychosocial 
measures were significantly correlated with DTI metrics for either group at p < 0.01. 
For FM patients, non-skeletonised ROIs showed significant negative associations 
with age and FA in several ROIs except left SII, ACC and left IPL (-0.62 < r < -0.38), 
while AD, RD, and MD were positively associated with age in most ROIs except SI 
bilaterally and ACC (0.48 < r < 0.68) (Table 2.5). Controls showed no significant 
associations of age and FA, however AD, RD, and MD were positively associated with 
age in all ROIs but left and right thalamus and left insula (0.45 < r < 0.66) (Table 2.5). 
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For correlations of DTI metrics within the WM skeleton, FM patients showed 
negative associations for age and FA (-0.63 < r < -0.54) and positive associations for 
other metrics (AD, RD, MD; 0.47 < r < 0.60) in the left and right thalamus (Table 2.6). 
Controls showed only negative correlation between age and left IPL FA (r = -0.47). In 
FM patients only, significant negative correlations of BMI were found in the right 
thalamus and AD (r = -0.50); right SI and left SII and AD, RD, and MD (-0.73 < r < -
0.48); and left IPL for AD (r = -0.52) and both IPL for RD and MD (-0.60 < -0.48) (Table 
2.6). 
Discussion 
Global and regional WM abnormalities in the brain of FM patients, as compared 
to age- and sex-matched healthy controls, are suggested based on the results reported 
here. Supporting a role for the CNS in FM pathophysiology, global abnormalities were 
found by reductions of diffusion anisotropy and increased radial and mean diffusivity 
along WM tracts associated with multiple functional roles including sensory, motor, 
visual, auditory and inter-hemispheric connectivity. Regional differences of diffusion 
patterns were also revealed in pain-related brain locations, further supporting CNS 
micro-structural abnormalities as a putative mechanism in FM. 
WM skeleton abnormalities in TBSS 
WM tracts are the “information highways” in the CNS, and have been traditionally 
divided in three groups according to their connectivity (Jellison et al., 2004; Wycoco et 
al., 2013): 
1. Projection fibers connect cortical areas with subcortical (deep nuclei) 
structures, brainstem, cerebellum and spinal cord, and can be subdivided 
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in corticofugal (efferent) and corticopetal (afferent). They include 
corticospinal, corticobulbar, and corticopontine tracts, thalamic radiations 
and geniculocalcarine tracts (optic radiations). 
2. Association fibers connect cortical areas within the same hemisphere. 
These fibers can be short range such as the subcortical U fibers 
connecting adjacent gyri, or long range including cingulum, superior and 
inferior fronto-occiptal fasciculi, uncinate fasciculus, superior longitudinal 
(arcuate) fasciculus and inferior longitudinal (occipto-temporal) fasciculus. 
3. Commissural fibers provide interconnection of similar cortical areas 
between the two hemispheres, and they include the corpus callosum and 
the anterior commissure. 
All the above WM tracts are typically identifiable in DTI color maps, and other 
tracts that are occasionally seen include optic tract, fornix, tapetum, and several fibers 
within the brainstem and cerebellum. 
Mean FA reductions in patients were localized within projection (corticospinal 
tracts, WM adjacent to SI / M1), association (inferior fronto-occiptal, inferior longitudinal 
and superior longitudinal fasciculi), and commissural (along all corpus callosum (genu, 
body, splenium)) fibers. Reduction in anisotropy, signaling potential WM abnormalities, 
within WM tracts that connect brain regions subserving different functional roles is in 
agreement with typical FM clinical symptoms, such as widespread pain, fatigue, and 
impaired cognition (Clauw, 2009). Projection fibers identified here with FA reductions 
potentially include corticospinal (motor control for body), corticobulbar (motor control for 
cranial nerves), and corticopontine (arises from precentral and postcentral gyri, with 
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contributory fibers from premotor, supplementary motor, posterior parietal, prefrontal 
and temporal cortices and project to pontine nuclei) tracts, as these fiber bundles run 
together and cannot be discriminated from each other via DTI data (Jellison et al., 2004). 
As these projection fibers project to their targets they contribute to form the internal 
capsule and its subdivisions (anterior limb, genu, posterior limb) in a somatotopic 
manner (Schuenke et al., 2007; Wycoco et al., 2013). Not surprising, significant 
differences in DTI metrics (reduced FA, increased RD and MD) in FM patients relative 
to controls have been found within the internal capsule as well. Intra-hemispherical 
connections served by long association fibers might also be affected in patients, as 
reduction in FA has been found within several fasciculi (inferior fronto-occiptal, inferior 
longitudinal and superior longitudinal). Functional roles of these fasciculi include 
integration of auditory and visual cortices to the prefrontal cortex, visual emotion and 
memory, and integration of auditory and speech nuclei (Wycoco et al., 2013). Finally, 
sensorimotor impairments and auditory hypersensitivity reported in FM might be a 
consequence of disturbed inter-hemispheric connectivity through the corpus callosum, 
as evidenced by overlapping altered DTI metrics values in patients relative to controls 
within this major WM bundle. In sum, several WM tracts that transmit information to and 
from different cortical areas show signs of WM abnormalities in FM and can potentially 
explain many symptoms that characterize the clinical presentation of affected patients. 
Of the 126,241 WM skeleton voxels tested for DTI metric differences between 
patients and controls, 7% showed reduced FA, while 8.2% and 8.5% showed increased 
RD and MD respectively with several tracts presenting superimposition of these metrics. 
Anisotropy within WM is a result of micro-structural barriers to water diffusion, including 
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axonal diameter and packing density, membrane permeability, and levels of myelination 
(Jones et al., 2013). The most commonly used anisotropy index is FA (Sundgren, 2009), 
and its value can be impacted by all those factors as well as the main fiber directionality 
(-ies) within a given voxel, .i.e., more than one main fiber orientation tends to reduce the 
FA measured in that voxel. For this reason, we also measured the mode (MO) of 
anisotropy as it provides insight into fiber orientations within a voxel. Despite finding 
significant reductions of MO for patients relative to controls over the corpus callosum 
and corona radiata, they represented only 17.2% of voxels showing FA reductions 
(1.2% of WM skeleton voxels). Therefore it seems unlikely that crossing fibers can fully 
explain the FA reductions in FM patients reported here. 
From the above, it follows that presence of micro-structural WM abnormalities in 
the brains of FM patients must be considered. Animal models of dysmyelination showed 
an increase in RD but no effects on AD (Song et al., 2002), thus in those WM tracts of 
FM patients presenting reduced FA and increased RD (but no AD changes) a process 
of myelin degradation could be in place. Increases in diffusivity as shown by MD in 
similar spatial locations further support this possibility, as myelin modulates the amount 
of anisotropy – but increased MD could also be a consequence of local inflammation 
and edema (Alexander et al., 2007). 
Global and regional differences of DTI metrics in the whole brain and WM skeleton 
Whole brain analysis for FA showed no significant differences between FM 
patients and controls however reduced AD and MD was found for patients; none of 
those differences were present for WM skeleton comparisons. Assessment of diffusion 
across all voxels within pain-related ROIs (including both GM and WM) showed a 
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reduction of MD within left and right SI. Both RD and AD were also reduced within SI 
bilaterally, but not FA – highlighting the importance of evaluating all DTI metrics for a 
more detailed understanding of WM micro-structure. Reduction of MD within SI is a 
curious finding, as apparent diffusion (which is proportional to MD) is usually stable 
across subjects and even mammalian species (Basser and Jones, 2002; Winston, 
2012), and as mentioned previously MD increases are usually interpreted as a sign of 
local water increase secondary to inflammation (Alexander et al., 2007), and decreases 
of this metric have been related to increased tumor cellularity (Gauvain et al., 2001) and 
to neuronal swelling evoked by excitotoxins including glutamate (Benveniste et al., 
1992). 
An abrupt local reduction change in apparent diffusion is a marker of a brain 
ischemic event (Moseley et al., 1990) with animal models showing 30-50% decrease in 
diffusion within the affected brain area in the acute phase, which is attributed mainly to 
cytotoxic edema (Le Bihan, 2003; Fung et al., 2011). Then a gradual increase of 
diffusion to baseline levels within 1-2 weeks (pseudonormalization) takes place, 
followed by a marked increased in the chronic stage as tissue disintegration ensues 
(Alexander et al., 2007). A similar time course for DTI metrics have been reported for 
the acute (↑ FA, ↓ MD), subacute (↓ FA, ↓ MD), and chronic (↓ FA, ↑ MD) stages (Fung 
et al., 2011). In the acute phase cytotoxic edema dominates with a consequent shift of 
water from the extra- to the intracellular space, with the consequent contraction of the 
former and restricted diffusion space in the latter supporting increased anisotropy. 
During the subacute period vasogenic edema develops thus increasing extracellular 
water content while persistent cytotoxic edema keeps intracellular water levels relatively 
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unchanged, reducing anisotropy but keeping mean diffusivity low. Chronic stage 
characteristic vasogenic edema persistence, gliosis and neuronal loss results in still 
reduce FA and an increase of MD (Fung et al., 2011). 
Reductions of MD within SI brain parenchyma reported here are much less 
intense compared to those in brain ischemia (left SI = 5.1%; right = 7%) and they 
represent group averages instead of individual brain changes. With these caveats in 
mind, one could hypothesize that the mechanisms underlying decreased MD in acute 
brain ischemic event may play a role for those findings within SI. WM and GM show 
different responses to ischemic injury, with WM presenting greater reductions in FA 
(Fung et al., 2011) since even minimal eigenvalue changes during ischemia within GM 
will lead to increases in FA due to the relative isotropic diffusion found in healthy GM. 
Our findings match this situation, where parenchymal SI presents with unchanged FA 
and reduced MD while the WM skeleton shows reduced anisotropy and increased MD 
supporting diffusion pattern changes in both GM and WM of SI. As cytotoxic edema 
arises from almost any brain insult including hypoxia, toxic or metabolic perturbations 
(Liang et al., 2007), it is tempting to speculate that blood hypoperfusion to SI may lead 
to a local, chronic ischemia able to trigger cytotoxic edema - thus reducing MD – but not 
severe enough to exceed cellular compensatory mechanisms (ionic pumps within 
plasma membrane) that prevents cell death. This hypothetical mechanism needs to be 
investigated using animal models of localized hypoperfusion in the brain. An alternative 
explanation would be local accumulation of excitotoxins such as glutamate within the SI 
region. It has been shown that a high interstitial concentration of glutamate is necessary 
to evoke cytotoxicity, in order to counterbalance uptake mechanisms that continuously 
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remove this neurotransmitter (Benveniste et al., 1992). Such scenario is supported by 
evidence that FM patients present abnormalities of “windup” phenomenon (Staud, 2006), 
which involves NDMA receptor mechanisms and glutamate is one of its main ligands. 
Glutamate is involved in neurotransmission in different levels across the somatosensory 
pathways (Broman, 1994), which includes mediation of SI neuronal responses to 
noxious stimulation (Pollard, 2000). Thus it is possible that a toxic accumulation of 
glutamate within SI parenchyma secondary to sustained input from peripheral tissues 
may lead to the present findings of reduced MD in this brain region. 
The left insula of patients showed reduced AD, RD, and MD within the WM 
skeleton (but not FA) relative to controls while no significant changes were found for its 
parenchymal mean values. The insula is an important brain region involved in a 
multitude of functions including nociception and pain processing (Craig, 2009), with 
functional MRI studies showing a role for it in both sensory-discriminative and affective-
emotional pain dimensions (Apkarian et al., 2005). Our findings point to reduced 
diffusion in all directions including along the dominant fiber direction (AD). The number 
of WM skeleton voxels captured by the mask representing the insula is relatively small, 
and these results may be an artifact despite the highly significant differences between 
the two groups. This finding must be investigated further in future studies. 
Correlational analyses found negative associations for DTI metrics and age, a 
well known effect reported by other groups in healthy subjects (Hsu et al., 2010; Lebel 
et al., 2012; Zhang et al., 2014). The mean BMI for FM patients was at the far end of the 
“overweight” classification but still not obese, however it was significantly different 
compared to the mean BMI for controls. Increased BMI in patients was associated with 
 51 
reduced mean diffusivity in right SI, left SII and IPL bilaterally. Studies using diffusion 
MRI found reduced MD values in otherwise healthy obese adults compared to non-
obese (Karlsson et al., 2013), and other recent studies also reported reductions of DTI 
metrics in obese subjects compared to non-obese (Stanek et al., 2011; Xu et al., 2013). 
Given our findings, future studies using diffusion MRI in FM patients may benefit from 
including a matching procedure for BMI for subjects across groups. 
Only three previous studies have used diffusion MRI in a sample of FM patients 
and controls. The pioneering study by Sundgren and colleagues reported a FA 
reduction in the right thalamus in patients relative to controls but no other differences 
were found in other pain-related ROIs or whole brain diffusivity (Sundgren et al., 2007). 
This result was replicated by a subsequent study, however it showed a much more 
complex pattern of differences between FM patients and controls that included both 
increase and decreases in FA in patients across ROIs (Lutz et al., 2008). Those results 
are not in agreements with the findings presented here. We used a priori defined 
anatomical ROIs instead of manually drawn ones, higher magnetic fields (3 vs. 1.5 
Tesla), and validated software packages for DTI data processing and analysis – all 
these are recent methodological advances that those studies did not benefit from, and a 
direct comparison of results must be done with caution. Recently a study using multiple 
MRI modalities including diffusion MRI found no differences for whole brain 
comparisons between younger and older FM patients and age-matched controls; ROI 
analyses based on clusters found in concurrent VBM analysis on the other hand 
detected decreased FA for older FM patients in the corpus callosum adjacent to the 
posterior cingulate cortex and marginally increased FA for younger patients in WM 
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medial to the left putamen (Ceko et al., 2013). None of these studies reported use of 
two techniques regarded as useful in minimizing data corruption that were part of the 
processing pipeline for the present study, namely cardiac-gated data acquisition and 
fieldmap-based geometric distortion correction, which may explain in part the discrepant 
findings. 
Other chronic pain conditions have been recently studied using DTI, including 
temporomandibular disorders (Moayedi et al., 2012; Wilcox et al., 2013), trigeminal 
neuralgia / neuropathy (Wilcox et al., 2013; Desouza et al., 2014) and chronic back pain 
(Mansour et al., 2013). This last study is noteworthy, as it followed recent onset back 
pain patients over time and found that a distinct pattern of WM abnormalities at baseline 
was predictive of pain persistence over one year. This study highlights the potential of 
using diffusion MRI to assess brain structural predisposition for developing chronic pain. 
In conclusion, FM patients presented abnormalities in several WM tracts 
compared to controls. The affected areas serve as connectivity pathways for several 
cortical areas serving diverse roles including sensorimotor and cognitive functions. 
Although a causal pathway cannot be inferred from this cross-sectional data, it provides 
further evidence for CNS involvement in FM pathophysiology. 
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Figures 
 
 
Figure 2.1. Diffusion tensor model and associated measures. A: Depiction of 
diffusion sphere and diffusion ellipsoid, with its respective eigenvectors and 
eigenvalues; B: Mode of anisotropy and its relation to the geometric shape of the 
tensor. 
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Figure 2.2. Regions of interest (ROI) masks used for DTI analyses. ROIs are 
shown in coronal view with their respective total and white matter skeleton only 
sizes (in voxels) (top panel). Sagittal view (bottom left) shows the thalamus 
(yellow), SI (red) and ACC (purple), while an axial view (bottom right) shows SI 
bilaterally (red). WM skeleton is represented by green lines. Voxel size = 1 mm3. 
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Figure 2.3. TBSS voxelwise results for between-group differences overlaid in 3D 
MNI brain template shown in sagittal view, highlighting the corpus callosum. 
Relative to controls, left panel shows FA reduction for patients (red); top right 
panel shows RD increase for patients (blue); bottom right panel shows MD 
increase for patients (purple). Right panels also show the FA maps (red), and 
overlap between FA and RD or MD in the respective panels is represented in 
yellow. WM skeleton is represented by green lines. A = anterior, P = posterior, S = 
superior, I = inferior, R = right. 
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Figure 2.4. TBSS voxelwise results for between-group differences overlaid in 3D 
MNI brain template shown in axial view, highlighting the corpus callosum and 
internal capsule. Relative to controls, left panel shows FA reduction for patients 
(red); top right panel shows RD increase for patients (blue); bottom right panel 
shows MD increase for patients (purple). Right panels also show the FA maps 
(red), and overlap between FA and RD or MD in the respective panels is 
represented in yellow. WM skeleton is represented by green lines. A = anterior, P 
= posterior, L = left, R = right. 
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Figure 2.5. TBSS voxelwise results for between-group differences overlaid in 3D 
MNI brain template shown in axio-coronal view, highlighting the corticospinal 
tracts. Relative to controls, left panel shows FA reduction for patients (red); top 
right panel shows RD increase for patients (blue); bottom right panel shows MD 
increase for patients (purple). Right panels also show the FA maps (red), and 
overlap between FA and RD or MD in the respective panels is represented in 
yellow. WM skeleton is represented by green lines. A = anterior, S = superior, L = 
left, R = right. 
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Figure 2.6. TBSS voxelwise results for between-group differences overlaid in 3D 
MNI brain template shown in axio-coronal view, highlighting the white matter 
adjacent to SI and M1. Relative to controls, left panel shows FA reduction for 
patients (red); top right panel shows RD increase for patients (blue); bottom right 
panel shows MD increase for patients (purple). Right panels also show the FA 
maps (red), and overlap between FA and RD or MD in the respective panels is 
represented in yellow. WM skeleton is represented by green lines. A = anterior, P 
= posterior, S = superior, L = left, R = right. 
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Figure 2.7. DTI metrics mean values for whole brain and WM skeleton voxels. Left 
panel shows whole brain FA (top) and AD, RD, and MD values (bottom). Mean 
values for WM skeleton voxels are depicted on the right panels for FA (top) and 
AD, RD, and MD (bottom). * = p < 0.05. 
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Tables 
 
Table 2.1. Locations with lower fractional anisotropy in FM patients compared to 
controls. 
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Table 2.4. Correlations for DTI metrics in the whole brain and white matter 
skeleton voxels. 
 
  
 64 
 
Table 2.5. Correlations for DTI metrics for non-skeletonised pain-related regions 
of interest. 
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Table 2.6. Correlations for DTI metrics in FM patients only for white matter 
skeletonised pain-related regions of interest. 
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CHAPTER 3: ASSESSMENT OF BRAIN MACRO-STRUCTURAL 
CHARACTERISTICS IN FIBROMYALGIA USING HIGH-RESOLUTION T1-
WEIGHTED ANATOMICAL IMAGING 
Introduction 
The brain is a relatively dynamic organ that can present functional and / or 
structural modifications in response to its various demands, so-called neuroplasticity. 
One such demand is persistent or chronic pain, where frequent nociceptive input can 
drive structural changes in the brain (May, 2008; Schmidt-Wilcke, 2008). Several 
studies using neuroimaging methods have provided evidence for these changes in 
different chronic pain conditions (Seifert and Maihofner, 2011; Smallwood et al., 2013). 
Based on these findings it has been proposed that chronic pain is not only a clinical 
symptom but a disease in its own right (Tracey and Bushnell, 2009), an opinion that has 
been embraced by many investigators (Doleys, 2010; Davis, 2013) but not all (Sullivan 
et al., 2013). 
Fibromyalgia (FM) is one such chronic pain condition, for which diverse lines of 
investigation support central nervous system (CNS) alterations that potentially 
contribute to its clinical presentation (Schweinhardt et al., 2008). Studies of brain macro-
structural characteristics in FM patients are relatively numerous, with the majority 
focusing on gray matter (GM) assessment using voxel-based morphometry (VBM) (May, 
2011) and a few others reporting other measures including brain volume estimates, 
cortical thickness and subcortical structures shape and volumetric analyses. The results 
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across VBM studies show discordant findings regarding location of GM differences and 
even the direction of change. Possible explanations for this include small sample sizes 
and differences in methodology for imaging data acquisition and processing. 
Our goal was to perform a comprehensive assessment of macro-structural brain 
features in a single, well characterized large sample of FM patients and age- and sex-
matched controls. We used high-resolution anatomical MRI images to investigate 
different structural aspects of the brain, including volume estimates for different tissue 
types, GM density and volume, subcortical structures volumes, and cortical and 
subcortical characteristics. 
Methods 
Imaging acquisition parameters 
Subjects were accommodated in the MRI scanner as described in chapter 1, 
methods section. A high-resolution T1-weighted anatomical image was acquired for 
each subject using a magnetization prepared rapid gradient echo (MP-RAGE) sequence 
(repetition time (TR) = 1,820 ms; echo time (TE) = 3.74 ms; inversion time (TI) = 900 
ms; flip angle = 8º; field of view = 256 mm; 1 x1 x 1 mm3 voxels; 160 slices acquired 
axially parallel to the anterior commissure-posterior commissure line; parallel imaging 
factor = 2 (GRAPPA)). 
Imaging data processing pipelines 
Processing steps for high-resolution T1-weighted anatomical images were done 
using two freely available neuroimaging software packages: 1) the Oxford Centre for 
Functional Magnetic Resonance Imaging of the Brain (FMRIB) software library (FSL v. 
5.0.5) (Smith et al., 2004; Jenkinson et al., 2012) (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki); and 
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2) Freesurfer image analysis suite v. 5.3.0 (http://surfer.nmr.mgh.harvard.edu/). Each 
analysis was processed using the necessary tool(s) from each software package, and 
are detailed below. 
Anatomical images were reoriented to match the MNI brain template orientation 
using the FSL tool “fslreorient2std” (with exception of the input images for subcortical 
structure segmentation (FSL’s SIENAX) and cortical surface reconstruction 
(Freesurfer)). Before any further processing, all anatomical images were loaded into 
FSLview and visually checked for any obvious artifacts. 
Brain tissue volumes estimation 
Brain tissue volumes, normalized for individual head size, were estimated using 
the FSL tool SIENAX (Smith et al., 2002). SIENAX uses as input the reoriented high-
resolution T1-weighted anatomical image and process it in a series of steps: 1) brain 
and skull images are extracted using the Brain Extraction Tool (BET) (Smith, 2002); 2) 
the brain image is affine-registered to the MNI152 standard brain template (available in 
FSL; http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases), using the skull image to determine the 
registration scaling. This step calculates a volumetric scaling factor, that is used for 
head size normalization; 3) tissue-type segmentation with partial volume estimation is 
carried out (Zhang et al., 2001) to calculate total volume of brain tissue. In addition, gray 
matter (GM), white matter (WM), peripheral GM and ventricular cerebrospinal fluid 
(CSF) estimates of volumes were also computed. 
Output files from SIENAX were visually checked for any problems. Volume 
estimates for each subject in mm3, normalized for head size, were used for statistical 
testing. 
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Gray matter assessment via voxel-based morphometry 
We used voxel-based morphometry (VBM) to assess the relative concentration of 
gray matter at the voxel level. This was accomplished using the validated FSL-VBM 
pipeline (Douaud et al., 2007) that applies an optimized VBM protocol (Good et al., 
2001). The reoriented anatomical images had non-brain tissue extracted using BET, 
then were GM segmented prior to non-linear registration to the MNI152 standard brain 
template. The resulting images were averaged and flipped along the x-axis to create a 
left-right symmetric, study-specific GM template. Subsequently, subject’s GM images 
were non-linearly registered to this study-specific template and "modulated" to correct 
for local expansion / contraction due to the non-linear component of the spatial 
transformation. The modulated GM images were concatenated into a 4D multi-subject 
image then smoothed with an isotropic Gaussian kernel with a sigma = 3 (full width at 
half maximum (FWHM) = 6.9 mm). The modulated, smoothed 4D multi-subject GM 
image was the input image for voxelwise and ROI analyses. 
For voxelwise analysis, a between-group permutation-based nonparametric t-test 
(Nichols and Holmes, 2002) using age as a covariate of no interest was done. This test 
was implemented via the FSL tool “randomise” with 5,000 permutations and using the 
threshold-free cluster enhancement option. This option allows the detection of clusters 
of significant voxels with no arbitrary thresholding while controlling for family-wise error 
rate across space, therefore correcting for multiple comparisons (Smith and Nichols, 
2009). This way, voxelwise statistics reported here were tested for significance at p-
value < 0.05, corrected. 
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For whole brain and ROI analysis, a priori defined anatomical brain regions were 
used that are commonly activated following noxious stimulation (Peyron et al., 2000; 
Apkarian et al., 2005), including the thalamus, primary (SI) and secondary (SII) 
somatosensory cortices, the insula, and the anterior cingulate cortex (ACC) (left / right 
separately except ACC). The inferior parietal lobule (IPL) was also included, which is a 
cortical area that integrates somatosensory and visual inputs and was activated 
following noxious pressure stimulus to the thumbnail during stimulus-evoked BOLD 
fMRI in the participating FM patients and controls (unpublished data). A binary mask 
image was generated for each of those ROIs using three probabilistic atlases available 
in FSL (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases), the Harvard-Oxford cortical and 
subcortical atlases (Desikan et al., 2006) and the Jülich histological atlas (Eickhoff et al., 
2006). From the Harvard-Oxford atlases we derived the ROI masks for right and left 
thalamus and insula, while the ACC mask was built as a single region; right and left SI, 
SII, and IPL were derived from the Jülich atlas. 
For each subject, the GM density was extracted for the whole brain and ROIs 
and then multiplied it by the volume of each region to calculate the GM volume in mm3. 
Subcortical structures segmentation and volumetric analysis 
Original anatomical images were processed using a FSL tool named “fsl_anat” 
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/fsl_anat), a fully automated processing pipeline with 
the goal of obtaining segmentation of subcortical structures. Relevant steps for our goal 
included reorienting original anatomical images to the MNI brain template orientation, 
automatic cropping of the image, bias-field correction, linear and non-linear registration 
to the MNI standard brain template, non-brain tissue extraction, and finally subcortical 
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structure segmentation. This final step used FIRST, a FSL tool that incorporates prior 
anatomical information from manually segmented images from 336 data sets that 
includes healthy and pathological (including cases of schizophrenia and Alzheimer’s 
disease) brains with an age range of 4-87 years (Patenaude et al., 2011). From this 
data, a 3D mesh model is created for each structure and fitted to the subject’s image, 
followed by a boundary correction to convert from a mesh-based to a volumetric 
representation. Fifteen different subcortical structures were segmented: brainstem 
(includes 4th ventricle), amygdala, caudate nucleus, hippocampus, nucleus accumbens, 
putamen, globus pallidus and thalamus (left/right separately except brainstem). Quality 
assessment for the processed data was done through visual check of the output images 
from the registration and segmentation steps. 
Volume measures in mm3 for all subcortical structures for each subject were 
determined and used for statistical testing. 
Assessment of brain cortical and subcortical characteristics 
Freesurfer image analysis suite was used to perform automated cortical surface 
reconstruction and volumetric segmentation of the original anatomical images for all 
subjects. Details of the procedures performed were previously described (Dale et al., 
1999; Fischl et al., 1999a; Fischl et al., 1999b; Fischl and Dale, 2000; Fischl et al., 
2001). In short, preprocessing included motion correction, intensity normalization (bias 
field correction), non-brain tissue removal, segmentation of subcortical WM, and 
separation of cerebral hemispheres. Gray / white matter and gray / CSF boundaries 
were identified and modeled as white matter and pial surfaces, respectively. Finally, 
automated topology correction and surface deformation following intensity gradients 
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took place to obtain cortical surface models (=mesh models from a non-uniform grid of 
triangles). Further processing included registration to a spherical atlas for cross-subject 
cortical geometry matching, and cortical parcellation into units based on the gyri / sulci 
structure for automated labeling (Fischl et al., 2004; Desikan et al., 2006). 
The triangles forming the mesh for the cortical surface model intersect at a vertex, 
which has an X, Y, Z index and it is assigned a value. Distance between vertices is 
approximately 1 mm. Cortical measurements included thickness (vertex by vertex 
distance between the white and pial surfaces), area (relative to the WM surface), and 
volume. Gyral WM volumetric measurement was determined by using curvature 
landmarks and WM surface information to assign to the underlying WM the same label 
as the cortical parcellation unit above it, using a distance constraint of 5 mm for label 
expansion (Salat et al., 2009a). 
For vertexwise analysis, we did between-group comparison of cortical thickness, 
area and volume using all subjects’ cortical models sampled to a common space 
surface (“fsaverage”; average of nondemented 40 brains 
(http://freesurfer.net/fswiki/Buckner40Testing)), and smoothed on the surface with a 10 
mm FWHM kernel. We used a Freesurfer tool (Qdec) to run a general linear model for 
group differences on each those measures using age as a covariate of no interest. 
ROI analyses used cortical parcellation units that were in approximately similar 
spatial locations as a priori anatomical pain-related regions (left / right separately except 
ACC): postcentral gyrus (SI+SII), insula, ACC (rostral+caudal ACC), and supramarginal 
gyrus (IPL) (Figure 3.4 and 3.5). Measures of cortical thickness (mm), area (mm2), and 
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volume (mm3) as well as gyral WM volume (mm3) for each ROI were used for statistical 
testing. 
Statistical analyses 
Unless otherwise noted, between-group differences were assessed using 
analysis of covariance with age as a covariate of no interest, with group status as 
independent variable and output measures of each of the aforementioned analysis 
pipelines as dependent variables. All statistical tests were done using SPSS v. 18, with 
significance thresholding of p < 0.05. 
We also assessed associations for each of the aforementioned dependent 
variables with subject’s clinical measures and psychosocial questionnaire scores using 
the Pearson’s correlation coefficient “r”. Correlations with p-value < 0.01 were deemed 
significant. 
Results 
Subjects demographics characteristics, clinical measures and questionnaires 
A full description of the FM patients and controls is presented in chapter 1, 
results section. 
Brain tissue volumes estimation 
We assessed volumes for total brain, GM only, WM only, peripheral GM 
(excluding subcortical (deep) GM structures such as the basal ganglia and brainstem) 
and ventricular CSF (Fig. 3.1) with age as a covariate. No statistical significant 
differences for between-group comparisons were found (Table 3.1). 
Correlations between volumes estimates and clinical variables for both groups 
were significant for age and GM (r for FM patients = -0.52; controls’ r = -0.53) and 
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peripheral GM (patients’ r = -0.54; controls’ r = -0.59) volumes, and ventricular CSF 
volume was positively associated with age for patients only (r = 0.56). This implies that 
increased age is associated with decreases in GM and peripheral GM volumes and to 
increased ventricular CSF volume. BMI had a negative association with total brain 
volume in FM patients only (r = -0.47), and the association with GM volume was close to 
significance (r = -0.46; p = 0.011) but not for WM volume (r = -0.39; p = 0.34). No 
significant correlations for volumes estimates and psychosocial variables were found at 
p = 0.01. 
Gray matter assessment via voxel-based morphometry 
GM density was estimated in a voxel-by-voxel fashion for the subjects included in 
this study (Fig 3.2, top panel). Voxelwise comparison found no significant between-
group differences at p < 0.05, corrected. The voxel with the lowest p-value (0.076) was 
located over the right cerebellar lobule V. We also estimated GM volume for the whole 
brain and for pain-related ROIs (Fig. 3.2, bottom panel). Similarly, no significant 
between-group differences were found (Table 3.2). 
Correlational analyses showed that age was negatively correlated with GM 
volume in the whole brain, left SI, left SII, and in both insula and IPL bilaterally for FM 
patients (-0.65 < r < -0.41) and for controls (except left insula and left IPL) (-0.66 < r < -
0.39). Pain duration in FM patients was negatively associated with GM volume in the left 
IPL (r = -0.51). Thus increased age is associated with reduced GM in both groups, while 
pain duration in patients is only associated with reductions of GM volume in the left IPL. 
No significant correlations were found between GM volume and psychosocial measures. 
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Subcortical structures segmentation and volumetric analyses 
Following the segmentation of subcortical structures, we estimated their volumes 
(Table 3.3). Between-group comparisons, corrected for age, showed significant 
volumetric increase in the right amygdala (p-value = 0.021) while the left amygdala 
volume difference approached significance (p = 0.064) (Fig. 3.3). 
When assessing correlations, age was negatively associated with volume of left 
and right thalamus (r = -0.48 and r = -0.44 respectively) and caudate nucleus (r = -0.52, 
r = -0.47) for FM patients. No clinical pain measures showed significant associations 
with subcortical structures volumes. Of the psychosocial measures, only PILL score 
showed a significant negative correlation with the left globus pallidus (r = -0.61; p < 
0.001) and right amygdala (r = -0.47; p = 0.008) for patients. This implies that increased 
somatic awareness is associated with reductions in volume for these structures. 
Assessment of brain cortical and subcortical characteristics 
Vextexwise analysis, corrected for age, found no significant group differences for 
cortical thickness, area or volume in neither of the cerebral hemispheres (data not 
shown). 
Likewise, no cortical measurements were significant for the ROI analyses (Table 
3.4), with an increase of left insula area for FM patients relative to controls close to 
significance (p = 0.057). For gyral WM volume measurements (Table 3.5), significant 
volume increases in the patient group were found for the ACC (p = 0.030) and the left 
insula (p = 0.019, Fig. 3.6) relative to controls. 
Negative correlations for age and cortical thickness were significant in the ACC, 
insula and supramarginal gyrus bilaterally in patients (-0.59 < r < -0.48) and controls (-
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0.60 < r < -0.37) (Table 3.6). Age and cortical volume were significantly associated for 
FM patients only in the left insula (r = -0.47), and supramarginal gyri (left = -0.61, right = 
-0.47). Of the psychosocial measures, only CSQ-R ignoring pain score for patients was 
positively correlated with left postcentral gyrus thickness (r = 0.58) implying that patients 
with greater scores for this coping strategy present with increased cortical thickness in 
brain regions associated with somatosensory processing. 
No significant associations for gyral WM volumes and demographic 
characteristics or clinical measures were found for either group. Somatic awareness, as 
measured by PILL scores, was negatively associated with bilateral supramarginal gyrus 
(left = -0.47, right = -0.48; both p < 0.01), right postcentral gyrus (r = -0.44; p = 0.015) 
and ACC (r = -0.47; p = 0.009) gyral WM volume (Fig. 3.7). Trait anxiety was negatively 
correlated with gyral WM volume in the left supramarginal gyrus (r = -0.48; p = 0.009) 
and right insula (r = -0.45; p = 0.012) (Fig. 3.7). 
Discussion 
Our findings provide an overall view of macro-structural brain features in FM 
patients. In line with findings described by previous studies, some of the measurements 
showed no significant differences compared to controls while others provide initial 
evidence of structural abnormalities that can help explain the symptomatology 
described for this condition. 
Volumes estimates for total brain, total GM, total WM, peripheral GM or 
ventricular CSF was no different between FM patients and controls, replicating findings 
from others (Burgmer et al., 2009; Ceko et al., 2013; Fallon et al., 2013). Two studies 
reported reduced total brain and GM volumes for patients compared to controls, one 
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with a relatively small sample size (Kuchinad 2007) and another that used a different 
methodology for volumes estimation (Jensen, 2013). 
VBM analysis of GM also showed no differences between groups for global GM 
density or pain-related ROIs. This is the most often used approach for brain structural 
assessment in FM, and the results reported are not always in agreement. Whole brain 
comparisons showed decrease of GM density / volume in several areas for FM patients 
as compared to controls including left thalamus, parahippocampal gyri, anterior and 
posterior cingulate cortices, insula, prefrontal cortical areas, left supplementary motor 
area and right premotor cortex (Kuchinad et al., 2007; Schmidt-Wilcke et al., 2007; 
Wood et al., 2009; Puri et al., 2010; Ceko et al., 2013). One study reported increases in 
GM for patients in the left orbitofrontal cortex, left cerebellum and striatum bilaterally 
(Schmidt-Wilcke et al., 2007) while another detected no group differences (Hsu et al., 
2009). When assessing GM differences within ROIs, FM patients showed reduced GM 
volumes in bilateral hippocampus, ACC, inferior frontal gyrus, left amygdala and left 
insula (Lutz et al., 2008; Burgmer et al., 2009; Robinson et al., 2011) – the latter 
difference was shown to be present for FM patients with depression but not for those 
without (Hsu et al., 2009). Each of these studies reported a different set of brain regions 
with altered GM volume, and the most concordant finding across most of them seems to 
be a decrease in GM in the ACC. Recently one study showed that, by splitting FM 
patients into younger and older cohorts, there is restricted directionality for the GM 
volumes differences: only increases for the younger FM cohort and only decreases for 
the older cohort were found when compared to age-matched controls respectively 
(Ceko et al., 2013). Interestingly, GM alterations have also been shown in healthy 
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controls lacking habituation to noxious stimulus (Stankewitz et al., 2013) and increased 
pain ratings are associated with decreases in GM density (Emerson et al., 2014). 
Therefore interpretation of GM density / volume differences or the lack thereof between 
patients and controls must be made with caution. 
Of the subcortical structures measured for total volume in the present study, only 
the amygdalae presented increased whole volume for FM patients compared to controls. 
A recent study using similar methodology found differences for brainstem volume but 
not for the amygdala (Fallon et al., 2013). One study reported a significant reduction of 
volume related to GM in the left amygdala (Burgmer et al., 2009) and another described 
a bilateral reduction for GM-related amygdala volume that did not survive multiple 
comparisons correction (Lutz et al., 2008). The amygdala is part of the limbic system, 
and it has been associated with emotions processing (Schulkin, 2006). While it is 
difficult to explain the discrepancies between our results and that of others, the 
emotional burden related to FM supported by our findings of psychosocial measures 
may induce neuroplastic changes in this region. 
Similarly to VBM analysis of GM volume, no significant differences were found for 
cortical thickness, area or volume for both vertexwise and ROI analyses. This is in 
contrast to the results of Jensen and colleagues, who reported reduced cortical 
thickness for FM patients in the left rostral ACC, and gyri within the frontal and temporal 
lobes (Jensen et al., 2013), while younger FM patients presented increased thickness 
(left insula, left SII, left premotor cortex, right superior temporal and right posterior 
parietal cortices) and older patients reduced thickness (right premotor /SII / M1 cortices, 
and posterior cingulate cortex and precuneus) compared to age-matched controls 
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(Ceko et al., 2013). This inconsistency relative to cortical thickness measurements 
reflects the inconsistent findings for GM volume analysis using VBM, and it is possible 
that these analyses are not sufficiently sensitive to detect potential differences in the 
cortical mantle of FM patients. 
Regional WM volumes comparisons showed increased volume for gyral WM 
adjacent to the ACC and left insula, and as mentioned before we found no differences 
for total WM volume between patients and controls. It has been suggested that WM 
volume loss can have specific patterns across brain space and over time in 
degenerative processes (Salat et al., 2009a). Our results showed increased volumes, 
while degenerative diseases affecting WM usually are related to volume reduction. One 
possible explanation is that a local inflammatory edema within these WM regions could 
cause a volumetric increase, and our findings of WM skeleton abnormalities within 
these regions may support this possibility (see chapter 2). 
Correlations of an inverse association of age and several GM volume measures 
were not surprising, as they are widely reported in the literature (Good et al., 2001). BMI 
negative association with total brain volume reinforces the need to match this parameter 
across groups in future studies. The inverse relationship of somatic awareness and 
amygdala volume for FM patients is curious, especially with our finding of increased 
volume of this structure in patients. Replication of these findings by future studies may 
help clarify this paradoxical situation. Finally, somatic awareness and trait anxiety were 
negatively associated with the WM gyral volume associated with several pain-related 
brain regions. This provides initial evidence that affective symptoms of FM impact not 
only cortical areas but also their associated WM. 
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In conclusion, brain macro-structural abnormalities in FM patients seem to be 
unrelated to global volumetric measures of GM or WM or cortical characteristics. 
Regional differences for amygdala volume and gyral WM adjacent to the ACC and left 
insula suggest that more localized changes may be involved in this condition’s 
pathophysiology. Future studies should investigate this possibility by using a priori 
defined anatomical regions, as well as functional ROIs derived from fMRI studies that 
are not restricted by anatomical boundaries. 
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Figures 
 
 
Figure 3.1. Brain segmentation for volumes estimates. GM is shown in blue, WM 
in white and ventricular CSF in red. 
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Figure 3.2. Study-specific gray matter (GM) template and regions of interest (ROI). 
The GM template was used for registration (top). Masks used to extract GM 
volume for each ROI (bottom): SI = red, SII = brown, Insula = light blue, ACC = 
green, IPL = dark blue. 
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Figure 3.3. Left and right amygdala volumes. * = p < 0.05. 
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Figure 3.4. Brain cortical parcellations and subcortical regions used for region of 
interest (ROI) analyses in 2D view. Left panel (axial view): The outer red line 
corresponds to the pial surface (GM / CSF boundary) and the internal yellow line 
corresponds to the WM / GM boundary. Right panels show same ROIs in coronal 
view. Arrows used to indicate each ROI use outer / inner colors corresponding to 
the GM and WM portions of the ROI respectively. 
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Figure 3.5. Brain cortical parcellations used for region of interest (ROI) analyses 
in 3D view. Left (top) and right (bottom) hemispheres are shown. Pial surface is 
shown in the outer panels, and the middle panel shows inflated surfaces. 
Numbers represent the ROIs: postcentral gyrus = 1, insula = 2; supramarginal 
gyrus = 3; ACC = 4. 
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Figure 3.6. Left and right insula gyral WM volumes. * = p < 0.05. 
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Figure 3.7. Correlations for gyral white matter volumes and questionnaire scores. 
* = p < 0.01. Correlations close to significance are also shown (0.01 ≤ p ≤ 0.015). 
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Tables 
Table 3.1. Brain tissue volumes estimates. 
 
  
 89 
 
Table 3.2. Gray matter volume as measured by voxel-based morphometry. 
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Table 3.3. Subcortical structures volume estimates. 
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Table 3.5. Gyral white matter volume measurements. 
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Table 3.6. Correlations between cortical measures and age. 
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CHAPTER 4: OVERALL IMPLICATIONS OF PRESENT FINDINGS AND 
FUTURE DIRECTIONS 
Present findings overview 
This dissertation describes a comprehensive investigation of structural brain 
features of a well characterized sample of FM patients, using the data from age- and 
sex-matched healthy controls as a reference. Our findings support the view that FM 
pathophysiology is related to brain abnormalities, not only due to functional impairment 
as reported in the literature but also secondary to its structural features. One strength of 
this project is the use of multimodal MRI with several quality measures to assess brain 
structure at both micro- and macro-scales. 
Cerebral tissue microscopic spatial arrangement can be probed using diffusion 
MRI, a non-invasive imaging technique that integrates microscopic displacement of 
water molecules within the brain parenchyma into a single parameter at a millimetric 
(voxel) resolution: the apparent diffusion coefficient (Le Bihan, 2003). Further 
mathematical modeling can provide even more information about diffusion directionality 
according to the main fibers orientation, and these can help us infer features of white 
matter (WM) tracts such as axonal and myelination status as well as perform in vivo 
tractography to better understand brain anatomical connectivity. We presented evidence 
that FM patients have abnormalities within major WM tracts connecting cortical areas 
that serve several functional roles, supporting an association between WM 
abnormalities and the multitude of symptoms commonly reported by these patients. 
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Recent studies show the potential of diffusion MRI to predict the transition to pain 
chronicity (Mansour et al., 2013), and this imaging technique can potentially help us 
understand brain-related risk factors for FM (see below) that might contribute to the 
wide variation of the clinical presentation of these patients, the so-called “fibromyalgia 
spectrum” (Wolfe et al., 2011). 
High-resolution brain anatomical imaging provides information on the macro-
structural level of the different cerebral tissues. This has been mostly used to assess 
gray matter (GM) volume / density in FM patients using voxel-based morphometry 
(VBM) with varying results. Our analyses investigated different characteristics of GM 
(brain volume estimates, VBM, cortical characteristics of thickness, area, and volume) 
and showed no significant differences between patients and controls. Our main findings 
were an increased volume in the amygdalae and for WM volumes adjacent to the ACC 
and left insula. Based on the incongruity of results for macro-structural brain 
abnormalities in FM reported in the literature and the present findings, it is possible that 
neuroplastic changes in the brains of FM patients have a more subtle and localized 
pattern within subcortical structures and WM. 
Our findings also support a view that brain structural abnormalities in FM are 
better detected at the micro-scale as previously suggested (Lutz et al., 2008), at least 
with the available present MRI technology. Diffusion MRI is a rapidly developing 
imaging technique, not only related to technological advancements in data acquisition 
but also the mathematical modeling of diffusion and the knowledge about the biological 
correlates of the different diffusion-related metrics. Future research of brain structural 
properties in FM will greatly benefit from these developments, and likely will help further 
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our understanding of central pathophysiological mechanisms underlying this complex 
condition. 
Future directions 
Neuroimaging has contributed largely to our current understanding of FM 
(Schweinhardt et al., 2008), and will likely play an expanding role in progressing it 
further. Refinement of experimental designs, disease classification systems and 
neuroimaging tools might allow the latter to play a role in the taxonomy of functional 
somatic syndromes (Browning et al., 2011). Use of neuroimaging to assess specific 
characteristics of pain syndromes may help bridge the gap between the genetic 
background to the presenting phenotype of a patient (Tracey, 2011). Collection of multi-
modal brain data from the same individual by means of neuroimaging techniques that 
provide complementary information is becoming a standard (Soares et al., 2013), an 
approach that we used in this study to some extent. Multi-modal brain neuroimaging 
provides a global overview of brain structure and function, and for complex conditions 
as FM this may be a fruitful way to improve the understanding of its pathophysiology. 
Other investigators have also realized that and successfully implemented such an 
approach (Ceko et al., 2013). 
FM usually presents in patients with one or more comorbid conditions – the so-
called functional somatic syndromes (FSS). It has been implied that this polysyndromic 
presentation arises from mechanisms that are common to these conditions (Yunus, 
2007). However, there are also differential characteristics between these comorbid 
conditions that seems specific to each of them (White, 2010). Given this dichotomous 
situation – FSSs can be both heterogeneous and associated with each other – an 
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interesting strategy has been proposed: for mechanisms that are believe to be shared 
among different FSSs, patients presenting with two or more FSS should be included in 
the subject sample; on the other hand if the interest is to understand what differentiates 
one FSS (e.g., FM) from others, a more “clean” subject sample presenting with FM only 
should be sought (Warren et al., 2013). Although attractive, this approach may be 
difficult to implement as FM patients most commonly present with one or more comorbid 
FSS than not – thus making the investigation of mechanisms unique to FM problematic. 
In order to investigate risk factors for a condition that might be related to its 
causal pathway, a longitudinal design is necessary (Grimes and Schulz, 2002). 
However this is difficult in rare conditions or those that do not have a clear onset such 
as FM. A longitudinal study with FM-free participants followed over time to detect those 
that develop the condition would be prohibitively expensive and taxing to the 
participants. An alternative approach can be suggested based on the acknowledged 
wide variation of FM clinical symptoms (“fibromyalgianess” (Wolfe et al., 2011)). Many 
studies looking to assess some type of characteristic across the lifespan do not usually 
follow individuals for years or decades but rather recruit a large sample of subjects 
representative of the age range of interest (Salat et al., 2009a; Salat et al., 2009b; Lebel 
et al., 2012). This strategy could be adapted to FM where a large sample of patients 
could be recruited across the spectrum of clinical symptomatology, i.e., from patients 
that fits diagnostic criteria yet have little or no comorbid conditions and are functional, to 
those patients that present with a plethora of symptoms and comorbidities and are 
functionally incapacitated. This “fibromyalgia spectrum span” approach could improve 
our understanding on the mechanisms that makes the burden of FM greater for a 
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subset of patients but not for others. Future investigations of FM using neuroimaging or 
other methods may benefit from such approach, with the ultimate goal of increasing our 
understanding of this puzzling and complex condition that deeply affects the lives of its 
sufferers. 
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